<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867412437346</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867412437346</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The science and practice of lithium therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Malhi</surname><given-names>Gin S</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412437346">1</xref>
<xref ref-type="aff" rid="aff2-0004867412437346">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tanious</surname><given-names>Michelle</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412437346">1</xref>
<xref ref-type="aff" rid="aff2-0004867412437346">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Das</surname><given-names>Pritha</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412437346">1</xref>
<xref ref-type="aff" rid="aff2-0004867412437346">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Berk</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="aff3-0004867412437346">3</xref>
<xref ref-type="aff" rid="aff4-0004867412437346">4</xref>
<xref ref-type="aff" rid="aff5-0004867412437346">5</xref>
<xref ref-type="aff" rid="aff6-0004867412437346">6</xref>
<xref ref-type="aff" rid="aff7-0004867412437346">7</xref>
</contrib>
</contrib-group>
<aff id="aff1-0004867412437346"><label>1</label>CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, Sydney, Australia</aff>
<aff id="aff2-0004867412437346"><label>2</label>Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia</aff>
<aff id="aff3-0004867412437346"><label>3</label>School of Medicine, Deakin University, Geelong, Australia</aff>
<aff id="aff4-0004867412437346"><label>4</label>Orygen Youth Health Research Centre, Parkville, Australia Centre for Youth Mental Health, University of Melbourne, Parkville, Australia</aff>
<aff id="aff5-0004867412437346"><label>5</label>Department of Psychiatry, University of Melbourne, Parkville, Australia</aff>
<aff id="aff6-0004867412437346"><label>6</label>Barwon Health and the Geelong Clinic, Swanston Centre, Geelong, Australia</aff>
<aff id="aff7-0004867412437346"><label>7</label>The Mental Health Research Institute, Parkville, Australia</aff>
<author-notes>
<corresp id="corresp1-0004867412437346">Gin S Malhi, CADE Clinic, Department of Psychiatry, Level 5, Building 36, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. Email: <email>gin.malhi@sydney.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>46</volume>
<issue>3</issue>
<fpage>192</fpage>
<lpage>211</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<p><bold>Introduction</bold>: Despite more that 60 years of clinical experience, the effective use of lithium for the treatment of mood disorder, in particular bipolarity, is in danger of becoming obsolete. In part, this is because of exaggerated fears surrounding lithium toxicity, acute and long-term tolerability and the encumbrance of life-long plasma monitoring. Recent research has once again positioned lithium centre stage and amplified the importance of understanding its science and how this translates to clinical practice.</p>
<p><bold>Objective</bold>: The aim of this paper is to provide a sound knowledge base as regards the science and practice of lithium therapy.</p>
<p><bold>Method</bold>: A comprehensive literature search using electronic databases was conducted along with a detailed review of articles known to the authors pertaining to the use of lithium. Studies were limited to English publications and those dealing with the management of psychiatric disorders in humans. The literature was synthesized and organized according to relevance to clinical practice and understanding.</p>
<p><bold>Results</bold>: Lithium has simple pharmacokinetics that require regular dosing and monitoring. Its mechanisms of action are complex and its effects are multi-faceted, extending beyond mood stability to neuroprotective and anti-suicidal properties. Its use in bipolar disorder is under-appreciated, particularly as it has the best evidence for prophylaxis, qualifying it perhaps as the only true mood stabilizer currently available. In practice, its risks and tolerability are exaggerated and can be readily minimized with knowledge of its clinical profile and judicious application.</p>
<p><bold>Conclusion</bold>: Lithium is a safe and effective agent that should, whenever indicated, be used first-line for the treatment of bipolar disorder. A better understanding of its science alongside strategic management of its plasma levels will ensure both wider utility and improved outcomes.</p>
</abstract>
<kwd-group>
<kwd>Bipolar disorder</kwd>
<kwd>lithium</kwd>
<kwd>mood stabilizer</kwd>
<kwd>neuroprotection</kwd>
<kwd>suicide</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0004867412437346" sec-type="intro">
<title>Introduction</title>
<p>Bipolar disorder (BD) is a lifelong illness characterized by periods of recurrent depression and mania. It presents clinically in a myriad of forms with a symptom profile that can vary considerably from one individual to the next (<xref ref-type="bibr" rid="bibr2-0004867412437346">Alda et al., 2009</xref>; <xref ref-type="bibr" rid="bibr112-0004867412437346">Malhi et al., 2009c</xref>). However, it is bipolar depression that exerts greater disability and generally requires more sophisticated treatment (<xref ref-type="bibr" rid="bibr118-0004867412437346">Malhi et al., 2003</xref>, <xref ref-type="bibr" rid="bibr111-0004867412437346">2009b</xref>, <xref ref-type="bibr" rid="bibr112-0004867412437346">2009c</xref>). More critical, however, is the need to confer mood stability and provide effective prophylaxis (<xref ref-type="bibr" rid="bibr115-0004867412437346">Malhi et al., 2012</xref>), and it is in this context that lithium truly distinguishes itself.</p>
<p>Rediscovered 60 years ago by John Cade for the treatment of BD (<xref ref-type="bibr" rid="bibr25-0004867412437346">Cade, 1949</xref>), lithium has been tested and trialled repeatedly against placebo and new comparators. The migration of anticonvulsants and then antipsychotics into the realm of lithium (<xref ref-type="bibr" rid="bibr117-0004867412437346">Malhi et al., 2011a</xref>) has steadily expanded the pharmacological armamentarium for the treatment of BD, making it significantly more complex (<xref ref-type="bibr" rid="bibr115-0004867412437346">Malhi et al., 2012</xref>). An additional level of sophistication has been brought about by the introduction of newly developed psychological therapies, social interventions and educational approaches (<xref ref-type="bibr" rid="bibr112-0004867412437346">Malhi et al., 2009c</xref>, <xref ref-type="bibr" rid="bibr114-0004867412437346">2009e</xref>). Remarkably, despite such dramatic changes lithium has managed to retain its salience, as evidenced by its prominent positioning in recent sets of guidelines (<xref ref-type="bibr" rid="bibr113-0004867412437346">Malhi et al., 2009d</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>). Its use for more than half a century, beginning with the treatment of BD and later in antidepressant augmentation, has generated a wealth of empirical evidence in addition to which it has been found to have a unique therapeutic profile that includes for instance its anti-suicidal and neuroprotective properties (<xref ref-type="bibr" rid="bibr72-0004867412437346">Grunze et al., 2009</xref>; <xref ref-type="bibr" rid="bibr108-0004867412437346">Malhi and Gershon, 2009</xref>; <xref ref-type="bibr" rid="bibr169-0004867412437346">van Erp et al., 2011</xref>). Despite being a veteran amongst putative mood stabilizers its ‘gold standard’ status has been protected by a raft of new data that have been spurred by an increase in the detection and diagnosis of BD.</p>
<p>The reasons for this growth, in particular over the past decade, are the subject of much debate but the emergence of new treatments for BD is undoubtedly either a cause or a consequence (<xref ref-type="bibr" rid="bibr117-0004867412437346">Malhi et al., 2011a</xref>). Most of these ‘novel’ medications are in fact ‘old drugs’ with a new indication, and the majority have initially focused on the acute phases of the illness, in particular mania. Of note, thus far none have managed to improve upon lithium, especially in terms of long-term treatment and prophylaxis (<xref ref-type="bibr" rid="bibr68-0004867412437346">Goodwin and Malhi, 2007</xref>; <xref ref-type="bibr" rid="bibr117-0004867412437346">Malhi et al., 2011a</xref>). By translating the Rosetta Stone of its mechanism of action into an understanding of the core pathophysiology of BD, lithium remains the critical key to unlocking the aetiology of the disorder.</p>
<p>In clinical practice the use of lithium has diminished somewhat in favour of other agents (<xref ref-type="bibr" rid="bibr106-0004867412437346">Malhi, 2010</xref>) and therefore doctors, especially those who have trained more recently, need to be reacquainted with its use. Therefore, this review provides a comprehensive and evidence-based practical guide to the administration of lithium therapy, in particular for the treatment of BD.</p>
</sec>
<sec id="section2-0004867412437346" sec-type="methods">
<title>Methods</title>
<p>A comprehensive search of peer-reviewed publications using MEDLINE, EMBASE and PsychINFO was conducted regarding the use of lithium in the treatment of BD. Keywords used to identify relevant articles and limit our search strategy included: adherence, bipolar depression, bipolar disorder, compliance, dosing schedules, hypomania, indications, lithium, maintenance therapy, mania, pharmacodynamics, pharmacokinetics, prophylaxis, regime, response, safety, side effects, suicide, tolerability and toxicity. In addition, literature known to the authors from books and book chapters was also scrutinized and the findings from the literature were then synthesized.</p>
<p>The paper is structured as follows. Initially, an outline of the science of lithium therapy is provided so as to aid an understanding of how lithium interacts with key systems within the body. The putative mechanisms of action of lithium are also briefly considered with respect to its psychotropic pharmacology. The therapeutic profile of lithium is then carefully reviewed examining both its efficacy, in particular in BD, and its tolerability is discussed next in the context of potential side effects, toxicity and poor compliance. Finally, the use of lithium in clinical practice is outlined with particular emphasis on practical aspects such as oral dosing, plasma monitoring and the tailoring of treatment to individual needs.</p>
</sec>
<sec id="section3-0004867412437346">
<title>The science of lithium therapy</title>
<sec id="section4-0004867412437346">
<title>Preparations</title>
<p>Clinically, lithium is administered as a salt in the form of lithium carbonate, lithium citrate, lithium chloride or lithium sulfate. Conjugation of lithium in these various forms alters its pharmacokinetics. In a study that compared the various lithium salts, it was found that the chloride and sulfate preparations reach peak plasma concentrations 1 hour after oral administration as compared to 4 hours for the carbonate preparation (<xref ref-type="bibr" rid="bibr4-0004867412437346">Altamura et al., 1977</xref>). This is because lithium carbonate is the least water-soluble of the various salts and as such is absorbed more slowly in the upper gastrointestinal tract than the others (<xref ref-type="bibr" rid="bibr4-0004867412437346">Altamura et al., 1977</xref>; <xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>). All three salts have similar pharmacokinetic properties with respect to volume of distribution, bioavailability and half-life (<xref ref-type="bibr" rid="bibr4-0004867412437346">Altamura et al., 1977</xref>; <xref ref-type="bibr" rid="bibr176-0004867412437346">Widerlov, 1976</xref>) and both immediate or slow release forms of lithium carbonate are currently available in Australia.</p>
<p>Slow release (SR) medications produce relatively more stable plasma lithium levels as compared to immediate release (IR) preparations because the latter are generally thought to result in greater peaks and troughs, but the evidence for this is somewhat equivocal. Some researchers have postulated that the peak plasma concentration of a SR lithium formulation is more likely to be delayed rather than lowered (<xref ref-type="bibr" rid="bibr60-0004867412437346">Fyro et al., 1970</xref>; <xref ref-type="bibr" rid="bibr80-0004867412437346">Johnson and Hunt, 1984</xref>; <xref ref-type="bibr" rid="bibr138-0004867412437346">Perry et al., 1981</xref>), but there is also evidence to suggest that peak plasma concentrations of SR lithium preparations are lower than those of IR preparations (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>; <xref ref-type="bibr" rid="bibr156-0004867412437346">Shelley and Silverstone, 1986</xref>), even though elimination rates do not differ significantly (<xref ref-type="bibr" rid="bibr156-0004867412437346">Shelley and Silverstone, 1986</xref>). Further, it should be noted that plasma lithium concentrations in patients taking SR lithium are not constant across individuals possibly because of individual differences in gastrointestinal tract functioning (<xref ref-type="bibr" rid="bibr60-0004867412437346">Fyro et al., 1970</xref>).</p>
</sec>
<sec id="section5-0004867412437346">
<title>Pharmacokinetics</title>
<p>Lithium is a naturally occurring ion that consequently is water-soluble, does not bind to plasma proteins and is able to cross the blood–brain barrier. It is absorbed predominantly through the stomach (<xref ref-type="bibr" rid="bibr60-0004867412437346">Fyro et al., 1970</xref>) without undergoing metabolism but is excreted almost exclusively by the kidney (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr161-0004867412437346">Sproule et al., 2000</xref>) (<xref ref-type="fig" rid="fig1-0004867412437346">Figure 1</xref>). Therefore, before commencing lithium therapy it is important to consider renal function and this can be assessed by measuring urea and electrolytes along with determining the creatinine clearance as indicated (see <xref ref-type="table" rid="table2-0004867412437346">Table 2</xref>). The latter is a product of muscle protein metabolism that is released into the blood circulation at a constant rate and distributed in total body water. Creatinine is therefore filtered passively through the glomerulus in proportion to the glomerular filtration rate (<xref ref-type="bibr" rid="bibr136-0004867412437346">Pachoreck, 2001</xref>) and if this decreases the excretion of lithium is impaired and its plasma levels increase, resulting in toxicity (see later).</p>
<fig id="fig1-0004867412437346" position="float">
<label>Figure 1.</label>
<caption>
<p>Pharmacokinetics and pharmacodynamics of lithium. This figure shows the effects of lithium on particular organs in the body as well as its movement through the nephron. <italic>Pharmacokinetics</italic>: Following <bold>oral ingestion</bold>, lithium is rapidly absorbed (1–6 hours) through the upper gastro-intestinal tract (GIT). Absorption time depends on inter-individual differences as well as the presence of food (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>; <xref ref-type="bibr" rid="bibr167-0004867412437346">Timmer and Sands, 1999</xref>). <bold>Peak plasma concentrations in the blood</bold> are reached 1–3 hours post administration for immediate release (<xref ref-type="bibr" rid="bibr4-0004867412437346">Altamura et al., 1977</xref>) and 4–12 hours for sustained release preparations (<xref ref-type="bibr" rid="bibr27-0004867412437346">Carson and Roberts, 2001</xref>; <xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>). <bold>Peak lithium concentrations in the brain</bold> are reached approximately 24 hours post ingestion due to the lower permeability of the blood–brain barrier (<xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>). The mechanisms of lithium transport in the nephron are shown in the diagram. <italic>Pharmacodynamics</italic>: Lithium acts on the thyroid gland and decreases the secretion of thyroxine, resulting in <bold>hypothyroidism</bold> in up to a fifth of patients (<xref ref-type="bibr" rid="bibr81-0004867412437346">Johnston and Eagles, 1999</xref>). In addition, lithium-treated patients may develop <bold>hypercalcaemia</bold> because of decreased calcitonin binding by parathyroid hormone (PTH) (<xref ref-type="bibr" rid="bibr105-0004867412437346">Mak et al., 1998</xref>; <xref ref-type="bibr" rid="bibr179-0004867412437346">Wilting et al., 2007</xref>). Lithium inhibits the action of antidiuretic hormone (ADH), without which water permeability in the luminal cells of the collecting duct membrane is reduced. This causes water to accumulate in the collecting duct and results in <bold>polyuria</bold> with less concentrated urine (<xref ref-type="bibr" rid="bibr1-0004867412437346">Agam et al., 2009</xref>; <xref ref-type="bibr" rid="bibr20-0004867412437346">Boton et al., 1987</xref>; <xref ref-type="bibr" rid="bibr105-0004867412437346">Mak et al., 1998</xref>; <xref ref-type="bibr" rid="bibr167-0004867412437346">Timmer and Sands, 1999</xref>; <xref ref-type="bibr" rid="bibr179-0004867412437346">Wilting et al., 2007</xref>). (ADH: antidiuretic hormone; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; H+: hydrogen; H<sub>2</sub>O: water; HCO<sup>3–</sup>: Hydrogen carbonate; K: potassium; PhP: phosphoproteins; PK: protein kinase; Li: lithium; Na: sodium, NaCl: sodium chloride; NH3: ammonia; V2: vasopressin receptor 2.)</p>
</caption>
<graphic xlink:href="10.1177_0004867412437346-fig1.tif"/>
</fig>
<p>Peak lithium plasma levels are reached 1–3 hours after administration of IR preparations (<xref ref-type="bibr" rid="bibr4-0004867412437346">Altamura et al., 1977</xref>) and 4–12 hours after SR preparations (<xref ref-type="bibr" rid="bibr27-0004867412437346">Carson and Roberts, 2001</xref>; <xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>). Lithium in the brain peaks about 24 hours after ingestion, and this is primarily due to the lower permeability of the blood–brain barrier (<xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>). After a day or so of lithium administration the mean ratio of its concentration in plasma to cerebrospinal fluid is 3.6:1 (<xref ref-type="bibr" rid="bibr161-0004867412437346">Sproule et al., 2000</xref>).</p>
<p>BD has higher rates of primary thyroid abnormalities than the general population (<xref ref-type="bibr" rid="bibr9-0004867412437346">Bauer et al., 2008</xref>), but treatment with lithium increases the likelihood of transient subclinical hypothyroidism (T3/T4 are normal but thyroid-stimulating hormone (TSH) is elevated). With longer term use overt hypothyroidism (reduced T3/T4 and elevated TSH) occurs in approximately 10% of patients and this figure is higher still in women (13%), and especially in those who start treatment between the ages of 40 and 60 years (20%) (<xref ref-type="bibr" rid="bibr81-0004867412437346">Johnston and Eagles, 1999</xref>; <xref ref-type="bibr" rid="bibr93-0004867412437346">Lazarus, 1998</xref>).</p>
<p>With similar properties to sodium and potassium ions, lithium has an entry point into renal cells but transport out of cells is more limited, and gradually this results in intracellular accumulation (<xref ref-type="bibr" rid="bibr167-0004867412437346">Timmer and Sands, 1999</xref>). Specifically, lithium is filtered completely in the glomeruli, and approximately 80% is reabsorbed in the proximal tubules (see <xref ref-type="fig" rid="fig1-0004867412437346">Figure 1</xref>). This obviates the need for further absorption in the loop of Henle and therefore the remainder accumulates in the collecting tubule (<xref ref-type="bibr" rid="bibr48-0004867412437346">Eyer et al., 2006</xref>; <xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr161-0004867412437346">Sproule et al., 2000</xref>).</p>
<p>Pharmacologically, lithium diminishes the response of cyclic adenosine monophosphate (cAMP) to antidiuretic hormone (ADH), which in turn limits the ability of the kidney to store free water. In conjunction with the accumulation of lithium in the collecting tubules, the effect of lithium on ADH decreases the ability of the kidneys to concentrate urine (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>). This predisposes individuals to the development of diabetes insipidus that can ultimately affect 10% of lithium-treated patients (<xref ref-type="bibr" rid="bibr11-0004867412437346">Bendz and Aurell, 1999</xref>). Though typically regarded a long-term side effect of lithium therapy, longitudinal studies suggest that a detectable impairment of renal concentrating ability may emerge within the first few years of exposure to lithium (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>).</p>
</sec>
<sec id="section6-0004867412437346">
<title>Pharmacodynamics</title>
<p>The pharmacodynamic properties of lithium are influenced by factors such as age, renal function, pregnancy and lactation as well as concomitant medication. All have an effect on plasma lithium levels. Clinicians therefore need to adjust the oral dose of lithium according to the circumstances of each individual ‘and monitor the plasma levels closely to ensure a therapeutic level is maintained and the risk of toxicity is minimized.</p>
<sec id="section7-0004867412437346">
<title>Age</title>
<p>With age, renal function declines (<xref ref-type="bibr" rid="bibr96-0004867412437346">Lindeman et al., 1985</xref>), and for those on lithium this translates to diminishing lithium clearance. Medical co-morbidities, such as chronic heart failure and hypertension that compromise renal clearance, are also increasingly more likely (<xref ref-type="bibr" rid="bibr54-0004867412437346">Fliser et al., 1997</xref>) and therefore, clinically, lower oral doses are needed to achieve therapeutic plasma levels in the elderly (<xref ref-type="bibr" rid="bibr45-0004867412437346">Eastham et al., 1998</xref>).</p>
<p>Further, elderly patients are often on multiple medications that can affect the concentration of lithium. For example, the net loss of sodium with diuretics leads to increased reabsorption in the proximal tubules. Thus, diuretics increase the plasma levels of lithium (<xref ref-type="bibr" rid="bibr166-0004867412437346">Thomsen and Leyssac, 1986</xref>) and therefore elderly patients generally require lower oral doses of lithium (about 25–30% lower) to achieve therapeutic plasma concentrations. Of note, levels should be monitored more closely when there are changes to primary or comorbid treatment (<xref ref-type="bibr" rid="bibr45-0004867412437346">Eastham et al., 1998</xref>; <xref ref-type="bibr" rid="bibr177-0004867412437346">Wijeratne and Draper, 2011</xref>; <xref ref-type="bibr" rid="bibr178-0004867412437346">Wilkinson et al., 2002</xref>).</p>
</sec>
<sec id="section8-0004867412437346">
<title>Renal function</title>
<p>The risk of lithium intoxication increases greatly for patients with abnormal renal function. In the case of acute renal dysfunction, the dose of lithium should be decreased and its plasma levels titrated to prevent toxicity. Renal insufficiency and nephritic syndrome are relative contraindications to lithium therapy (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>; <xref ref-type="bibr" rid="bibr126-0004867412437346">Morriss et al., 2008</xref>); however, moderate renal dysfunction can be managed provided lithium levels are closely monitored. This option should be considered in cases where lithium has been shown to be an effective prophylactic treatment (<xref ref-type="bibr" rid="bibr61-0004867412437346">Gash et al., 1995</xref>).</p>
</sec>
<sec id="section9-0004867412437346">
<title>Pregnancy and lactation</title>
<p>Bipolar disorder has implications for women as regards their ability to maintain wellness and have a family. Women of childbearing age and pregnant women with BD that have been exposed to lithium in the first trimester of pregnancy possibly incur an increased risk of congenital heart failure (<xref ref-type="bibr" rid="bibr112-0004867412437346">Malhi et al., 2009c</xref>). Specifically, the risk of Ebstein’s anomaly is thought to be slightly elevated in the first trimester (4–12%) as compared to the general population (2–4%) (<xref ref-type="bibr" rid="bibr37-0004867412437346">Cohen et al., 1994</xref>; <xref ref-type="bibr" rid="bibr173-0004867412437346">Viguera and Cohen, 1998</xref>); however, recently this figure has been considered to be an overestimation (<xref ref-type="bibr" rid="bibr104-0004867412437346">McKnight et al., 2012</xref>). In practice, the risk–benefit ratio of lithium therapy during the first trimester needs to be considered carefully on a case-by-case basis.</p>
<p>Further, all pregnant women with BD should have their mood monitored closely as they are a population at increased risk of relapse (<xref ref-type="bibr" rid="bibr112-0004867412437346">Malhi et al., 2009c</xref>). This is because during pregnancy the glomerular filtration rate increases and this in turn increases lithium clearance by up to 50%. The plasma lithium levels therefore fall significantly and put the mother at potential risk of relapse (<xref ref-type="bibr" rid="bibr99-0004867412437346">Llewellyn et al., 1998</xref>). Further, following childbirth, the mother’s blood volume rapidly returns to normal along with the rate of renal clearance of medications. Therefore, pregnant women need to reduce the dose of lithium or temporarily stop treatment 1 or 2 days prior to the expected delivery date (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>), or have a treatment plan to increase hydration (<xref ref-type="bibr" rid="bibr99-0004867412437346">Llewellyn et al., 1998</xref>) in order to prevent lithium intoxication. Post delivery, mothers should reinstitute treatment immediately as the risk of relapse at this time is more than threefold higher (80% risk of relapse as compared to 24% in non-pregnant women) (<xref ref-type="bibr" rid="bibr173-0004867412437346">Viguera and Cohen, 1998</xref>).</p>
<p>Like many drugs, lithium is excreted in breast milk and as a consequence plasma levels in infants whose mothers are taking lithium are often high (30–50% that of the mother) (<xref ref-type="bibr" rid="bibr174-0004867412437346">Viguera et al., 2007</xref>; <xref ref-type="bibr" rid="bibr185-0004867412437346">Yoshida et al., 1999</xref>). Hence, mothers who require lithium therapy may need to reconsider breastfeeding in the context of an individualized risk–benefit assessment (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>). Should the mother continue to breastfeed, the infant needs to be monitored closely for toxicity as the effects of lithium on infants are not known (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr185-0004867412437346">Yoshida et al., 1999</xref>).</p>
</sec>
<sec id="section10-0004867412437346">
<title>Co-medication</title>
<p>Co-administered medications can potentially increase lithium retention in the body. For instance, diuretics increase water clearance and this in turn decreases lithium clearance, especially those diuretics that act by depleting sodium (<xref ref-type="bibr" rid="bibr135-0004867412437346">Okusa and Crystal, 1994</xref>). Non-steroidal anti-inflammatory drugs (<xref ref-type="bibr" rid="bibr139-0004867412437346">Phelan et al., 2003</xref>), angiotensin converting enzyme (ACE) inhibitors (<xref ref-type="bibr" rid="bibr52-0004867412437346">Finley et al., 1996</xref>) and withdrawal of caffeine (<xref ref-type="bibr" rid="bibr125-0004867412437346">Mester et al., 1995</xref>) have also been shown to increase plasma lithium concentrations, although the mechanism by which this occurs is not yet well known (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>; <xref ref-type="bibr" rid="bibr135-0004867412437346">Okusa and Crystal, 1994</xref>; <xref ref-type="bibr" rid="bibr139-0004867412437346">Phelan et al., 2003</xref>). Nevertheless, lithium dosage should be reduced when co-prescribing with these medications (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>).</p>
</sec>
</sec>
<sec id="section11-0004867412437346">
<title>Biology and mechanisms of action</title>
<sec id="section12-0004867412437346">
<title>Neurotransmitters</title>
<p>The precise mechanisms by which lithium achieves its many therapeutic benefits is not yet fully understood; however, a substantive body of evidence implicates a number of neutrotransmitters.</p>
</sec>
<sec id="section13-0004867412437346">
<title>Glutamate</title>
<p>For instance, lithium has been shown to have effects on the excitatory neurotransmitter glutamate, the concentrations of which appear to be increased in mania and decreased in depression (<xref ref-type="bibr" rid="bibr15-0004867412437346">Berk and Malhi, 2011</xref>). Studies on both monkey and mouse cerebrocortical slices suggest that acute lithium administration increases the availability of glutamate in the post-synaptic neuron via NMDA (<italic>N</italic>-methyl <sc>d</sc>-aspartate) receptor stimulation (<xref ref-type="bibr" rid="bibr74-0004867412437346">Hokin et al., 1996</xref>) and by inhibition of its uptake via glutamate transporters (<xref ref-type="bibr" rid="bibr44-0004867412437346">Dixon and Hokin, 1998</xref>). This may, in part, explain the antidepressant properties of lithium, but how it achieves specificity in this regard remains unclear. Interestingly, with chronic lithium administration (1–2 weeks), the NMDA receptor is down-regulated and glutamate re-uptake is up-regulated, underpinning possibly its anti-manic effects. Further, chronic lithium administration eventually restores glutamate uptake to ‘normal’ levels, a change that is again in keeping with its longer-term mood-stabilising properties (<xref ref-type="bibr" rid="bibr44-0004867412437346">Dixon and Hokin, 1998</xref>).</p>
</sec>
<sec id="section14-0004867412437346">
<title>Dopamine</title>
<p>Dopamine (DA) is another neurotransmitter that has been found to increase in patients with mania and hence is a potential target for the action of lithium (<xref ref-type="bibr" rid="bibr142-0004867412437346">Post et al., 1980</xref>). Indeed, studies in rats have shown that, when treated with a DA re-uptake inhibitor, lithium-treated rats had lower levels of DA compared to those that were lithium naïve (<xref ref-type="bibr" rid="bibr50-0004867412437346">Ferrie et al., 2005</xref>, <xref ref-type="bibr" rid="bibr51-0004867412437346">2006</xref>). This suggests that lithium modulates the synthesis and/or release of DA in the presynaptic terminal. In addition, lithium may also exert its effects on post-synaptic DA transmission by attenuating G-protein functioning and inhibiting downstream second messenger systems such as adenlyl cyclase and cyclic adenosine monophosphate pathways (<xref ref-type="bibr" rid="bibr122-0004867412437346">Manji and Lenox, 2000</xref>).</p>
</sec>
<sec id="section15-0004867412437346">
<title>GABA</title>
<p>A third neurotransmitter that lithium increases the concentration of within the brain is the inhibitory neurotransmitter γ-aminobutyric acid (GABA), and theoretically this change might decrease neural over-excitation and thereby alleviate mania (<xref ref-type="bibr" rid="bibr24-0004867412437346">Brunello and Tascedda, 2003</xref>; <xref ref-type="bibr" rid="bibr94-0004867412437346">Lenox et al., 1998</xref>; <xref ref-type="bibr" rid="bibr143-0004867412437346">Post et al., 2003</xref>).</p>
</sec>
</sec>
<sec id="section16-0004867412437346">
<title>Second messenger signaling</title>
<sec id="section17-0004867412437346">
<title>GSK-3</title>
<p>Glycogen synthase kinase-3 (GSK-3) is an important downstream target of monoaminergic neurotransmission and has direct involvement in modulating synaptic plasticity, cell structure and resilience, and has been recently identified as a prominent target for lithium’s therapeutic and neuroprotective effects (<xref ref-type="bibr" rid="bibr17-0004867412437346">Berk et al., 2010b</xref>; <xref ref-type="bibr" rid="bibr78-0004867412437346">Ikonomov and Manji, 1999</xref>; <xref ref-type="bibr" rid="bibr103-0004867412437346">Machado-Vieira et al., 2009b</xref>; <xref ref-type="bibr" rid="bibr134-0004867412437346">O’Brien and Klein, 2009</xref>). Increased GSK-3 has been shown to be associated with behaviours of mania in mice (<xref ref-type="bibr" rid="bibr124-0004867412437346">Marmol, 2008</xref>) and lithium has been shown to directly inhibit GSK-3, contributing therefore to its anti-manic properties (<xref ref-type="bibr" rid="bibr78-0004867412437346">Ikonomov and Manji, 1999</xref>; <xref ref-type="bibr" rid="bibr103-0004867412437346">Machado-Vieira et al., 2009b</xref>). However, in some individuals BD is increasingly being regarded as a neurodegenerative disease with patients displaying atrophy in multiple brain regions compared to healthy controls (<xref ref-type="bibr" rid="bibr149-0004867412437346">Savitz and Drevets, 2009</xref>). In this context the inhibition of GSK-3 by lithium perhaps explains its neuroprotective properties (<xref ref-type="bibr" rid="bibr165-0004867412437346">Tajes et al., 2009</xref>), in particular its defence against cell death caused by excessive excitatory neurotransmission such as during a manic episode (<xref ref-type="bibr" rid="bibr34-0004867412437346">Chiu and Chuang, 2010</xref>; <xref ref-type="bibr" rid="bibr143-0004867412437346">Post et al., 2003</xref>).</p>
</sec>
<sec id="section18-0004867412437346">
<title>Inositol</title>
<p>One of the most widely accepted hypotheses for lithium’s mode of action is the ‘inositol depletion hypothesis’. Briefly, inositol is responsible for maintaining myo-inositol levels (mI), which in turn maintain phospholipid concentrations of cell membranes. Phospholipids are important for the binding of secondary messengers such as diaglycerol and inositol triphosphate (<xref ref-type="bibr" rid="bibr122-0004867412437346">Manji and Lenox, 2000</xref>), which are involved in receptor-mediated signal transduction within the central nervous system (CNS) (<xref ref-type="bibr" rid="bibr102-0004867412437346">Machado-Vieira et al., 2009a</xref>; <xref ref-type="bibr" rid="bibr78-0004867412437346">Ikonomov and Manji, 1999</xref>). Hence, the maintenance of mI levels is important for the efficiency of cellular signaling (<xref ref-type="bibr" rid="bibr43-0004867412437346">Deranieh and Greenberg, 2009</xref>).</p>
<p>In both in vivo and in vitro studies, lithium has been shown to interfere with the recycling of inositol, reducing its availability and thus reducing cellular signaling (<xref ref-type="bibr" rid="bibr122-0004867412437346">Manji and Lenox, 2000</xref>). It is hypothesized that lithium acts on regions of the brain where inositol is in excess, and indeed preliminary evidence from magnetic resonance imaging studies shows that mI levels are increased in mania and depression but unchanged in euthymic patients (<xref ref-type="bibr" rid="bibr33-0004867412437346">Chen et al., 1999</xref>; <xref ref-type="bibr" rid="bibr78-0004867412437346">Ikonomov and Manji, 1999</xref>). Furthermore, lithium does not inhibit inositol in euthymic patients, which lends support to the hypothesis that lithium only reduces the levels of inositol when these are in excess (<xref ref-type="bibr" rid="bibr158-0004867412437346">Silverstone et al., 2005</xref>).</p>
</sec>
</sec>
</sec>
<sec id="section19-0004867412437346">
<title>Clinical profile</title>
<sec id="section20-0004867412437346">
<title>Efficacy within BD</title>
<sec id="section21-0004867412437346">
<title>Acute mania</title>
<p>The efficacy of lithium as a first-line treatment in acute mania has been demonstrated in clinical trials spanning several decades (<xref ref-type="bibr" rid="bibr6-0004867412437346">Baldessarini and Tondo, 2000</xref>). The evidence from robust randomized controlled trials suggests that lithium is efficacious in the treatment of mania when compared to valproate (<xref ref-type="bibr" rid="bibr22-0004867412437346">Bowden et al., 2010</xref>; <xref ref-type="bibr" rid="bibr184-0004867412437346">Yildiz et al., 2011</xref>), and antipsychotics such as olanzapine and risperidone (<xref ref-type="bibr" rid="bibr152-0004867412437346">Segal et al., 1998</xref>; <xref ref-type="bibr" rid="bibr155-0004867412437346">Shafti, 2010</xref>; <xref ref-type="bibr" rid="bibr184-0004867412437346">Yildiz et al., 2011</xref>) or placebo (<xref ref-type="bibr" rid="bibr62-0004867412437346">Geddes et al., 2004</xref>; <xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>; <xref ref-type="bibr" rid="bibr72-0004867412437346">Grunze et al., 2009</xref>; <xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>; <xref ref-type="bibr" rid="bibr184-0004867412437346">Yildiz et al., 2011</xref>). Consequently, the majority of clinical practice guidelines recommend lithium monotherapy as a first-line option for the treatment of acute mania (<xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>, <xref ref-type="bibr" rid="bibr113-0004867412437346">2009d</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>, <xref ref-type="bibr" rid="bibr182-0004867412437346">2006</xref>) even though in practice its anti-manic action can take up to 6–10 days to take full effect. This is significantly slower than most atypical antipsychotics and so in reality lithium in combination with an antipsychotic is a better option for the treatment of more severe mania than monotherapy of either agent (<xref ref-type="bibr" rid="bibr72-0004867412437346">Grunze et al., 2009</xref>; <xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>; <xref ref-type="bibr" rid="bibr168-0004867412437346">Tohen et al., 2002</xref>).</p>
</sec>
<sec id="section22-0004867412437346">
<title>Acute bipolar depression</title>
<p>The evidence for lithium monotherapy in the treatment of acute depression is not as impressive as for acute mania partly because lithium takes 6–8 weeks to achieve an antidepressant effect, but also because in practice depression often has important psychological and social contributors to its variance, and requires a correspondingly broader therapeutic approach. Studies have shown that lithium is more likely to be effective when used to treat ‘classic’ BD (<xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>) in which there are discrete episodes of recurrent bipolar depression separated by distinct periods of remission. Therefore, the evidence from bipolar depression randomized controlled trials is skewed by high withdrawal rates because of prior exposure that obscures efficacy, and the inclusion of patients without bipolar I (<xref ref-type="bibr" rid="bibr56-0004867412437346">Fountoulakis et al., 2008a</xref>). Indeed, recent reviews acknowledge a lack of good quality randomized controlled trials for lithium in bipolar depression, making it difficult to evaluate its efficacy using meta-analyses (<xref ref-type="bibr" rid="bibr170-0004867412437346">Van Lieshout and MacQueen, 2010</xref>; <xref ref-type="bibr" rid="bibr172-0004867412437346">Vieta et al., 2010</xref>).</p>
<p>Interestingly, more recent clinical trials show that when compared with placebo lithium fails to achieve significant superiority (<xref ref-type="bibr" rid="bibr19-0004867412437346">Bhagwagar and Goodwin, 2002</xref>; <xref ref-type="bibr" rid="bibr55-0004867412437346">Fountoulakis, 2010</xref>; <xref ref-type="bibr" rid="bibr170-0004867412437346">Van Lieshout and MacQueen, 2010</xref>). Nevertheless, lithium is widely regarded as an important agent in the treatment of bipolar depression by current clinical practice guidelines (<xref ref-type="bibr" rid="bibr71-0004867412437346">Grandjean and Aubry, 2009c</xref>; <xref ref-type="bibr" rid="bibr172-0004867412437346">Vieta et al., 2010</xref>; <xref ref-type="bibr" rid="bibr183-0004867412437346">Yatham et al., 2009</xref>).</p>
</sec>
<sec id="section23-0004867412437346">
<title>Maintenance and prophylaxis</title>
<p>Lithium monotherapy has demonstrated superiority in the prophylaxis of mania, depression, and suicidal behaviour (<xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>; <xref ref-type="bibr" rid="bibr186-0004867412437346">Young and Hammond, 2007</xref>) both in earlier studies conducted in the 1970s that specifically appraised lithium and in more recent studies where it has been used as a comparator for newer agents (<xref ref-type="bibr" rid="bibr42-0004867412437346">Coryell, 2009</xref>). Starting maintenance early provides the best likelihood of good long-term outcomes (<xref ref-type="bibr" rid="bibr58-0004867412437346">Freeman and Freeman, 2006</xref>; <xref ref-type="bibr" rid="bibr62-0004867412437346">Geddes et al., 2004</xref>) and the BALANCE study has underscored the real world effectiveness of lithium as a true prophylactic agent (<xref ref-type="bibr" rid="bibr63-0004867412437346">Geddes et al., 2010</xref>). A recent meta-analysis of clinical trials showed that lithium therapy reduces the overall risk of relapse by 40–61% and that its effect in preventing a manic relapse is more pronounced than for depression (40% decreased risk compared with 22%) (<xref ref-type="bibr" rid="bibr62-0004867412437346">Geddes et al., 2004</xref>). Further, abrupt cessation or reduction of lithium levels during maintenance therapy can cause a recurrence of symptoms and lead to relapse in 60–80% of patients (<xref ref-type="bibr" rid="bibr28-0004867412437346">Cavanagh et al., 2004</xref>; <xref ref-type="bibr" rid="bibr87-0004867412437346">Klein et al., 1992</xref>; <xref ref-type="bibr" rid="bibr137-0004867412437346">Perlis et al., 2002</xref>; <xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>).</p>
<p>Recent reviews of prospective placebo controlled trials in well-characterized BD populations that achieved plasma lithium concentrations of 0.8–1.2 mmol/L, report effective prophylaxis (<xref ref-type="bibr" rid="bibr71-0004867412437346">Grandjean and Aubry, 2009c</xref>), but an optimal effect may be achievable at lower doses (<xref ref-type="bibr" rid="bibr137-0004867412437346">Perlis et al., 2002</xref>).</p>
</sec>
<sec id="section24-0004867412437346">
<title>Rapid cycling and mixed states</title>
<p>Rapid cycling, defined by the occurrence of four or more episodes per year, occurs in 13–20% of bipolar patients (<xref ref-type="bibr" rid="bibr66-0004867412437346">Goldberg and Berk, 2010</xref>). Conditions such as hypothyroidism, antidepressants and substance abuse possibly contribute to the development of rapid cycling (<xref ref-type="bibr" rid="bibr41-0004867412437346">Coryell, 2005</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>), and this is a concern because patients that are rapid cycling are often less responsive and less adherent to treatment than those with conventional patterns of BD. Further, in clinical practice, rapid cycling presentations can be difficult to reliably differentiate from mixed episodes and manifestations of borderline personality (<xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>). The traditional view is that lithium is less effective in rapid cycling and mixed states, especially in terms of preventing relapse, though there is evidence that it decreases symptom severity and reduces morbidity (<xref ref-type="bibr" rid="bibr41-0004867412437346">Coryell, 2005</xref>; <xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>; <xref ref-type="bibr" rid="bibr128-0004867412437346">Muzina, 2009</xref>; <xref ref-type="bibr" rid="bibr164-0004867412437346">Suppes et al., 2008</xref>). Therefore, on balance, current wisdom advocates the use of lithium for rapid cycling in combination with other psychotropic drugs, particularly atypical antipsychotics (<xref ref-type="bibr" rid="bibr41-0004867412437346">Coryell, 2005</xref>; <xref ref-type="bibr" rid="bibr71-0004867412437346">Grandjean and Aubry, 2009c</xref>; <xref ref-type="bibr" rid="bibr128-0004867412437346">Muzina, 2009</xref>).</p>
</sec>
<sec id="section25-0004867412437346">
<title>Positioning in guidelines</title>
<p>The positioning of lithium in the majority of clinical practice guidelines reflects its efficacy in treating the respective phases of BD (<xref ref-type="fig" rid="fig2-0004867412437346">Figure 2</xref>). By definition, treatment guidelines are designed to inform clinicians of best practice and the evidence for this is usually based on clinical trial data. This has some inherent limitations. First, the ‘types’ of BD studied in clinical trials has undergone significant transformation with a shift towards BD II and bipolar spectrum disorders; second, most clinical trials are of relatively short duration (12–16 weeks) and therefore do not reflect the reality of lifelong treatment; third, there is a paucity of high-quality data from which to extrapolate to real-world management (<xref ref-type="bibr" rid="bibr131-0004867412437346">Nivoli et al., 2011</xref>); and lastly, because of service filter effects, most trials in academic tertiary centres in the developed world unwittingly concentrate on the most ill and refractory individuals, skewing results towards the negative. It is because of this that there are many discrepancies between guidelines and therefore in addition to using the evidence it is important to draw on experience to create individualized treatment regimens (<xref ref-type="bibr" rid="bibr112-0004867412437346">Malhi et al., 2009c</xref>). In this context, lithium has a substantive empirical evidence base and has therefore managed to retain prominence in most clinical practice guidelines.</p>
<fig id="fig2-0004867412437346" position="float">
<label>Figure 2.</label>
<caption>
<p>Summary of the current recommendations for lithium use in phases of illness of BD. Lithium is recommended as a first-line treatment by all guidelines across all phases of the illness. <italic>Mania</italic>: Lithium is recommended in combination with an atypical antipsychotic for severely ill patients (<xref ref-type="bibr" rid="bibr5-0004867412437346">APA, 2002</xref>; <xref ref-type="bibr" rid="bibr113-0004867412437346">Malhi et al., 2009d</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>) or monotherapy for less ill patients (<xref ref-type="bibr" rid="bibr5-0004867412437346">APA, 2002</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>). <italic>Depression</italic>: Lithium monotherapy is recommended first-line, and the addition of an atypical antipsychotic or second mood stabilizer should be considered if the patient is not already on treatment (<xref ref-type="bibr" rid="bibr5-0004867412437346">APA, 2002</xref>; <xref ref-type="bibr" rid="bibr113-0004867412437346">Malhi et al., 2009d</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>). <italic>Rapid cycling</italic>: Lithium monotherapy is not as effective in rapid cycling BD but is recommended as a first-line option in combination with other treatments (<xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>). It is also a valid second-line treatment for this phase after atypical antipsychotic medications or valproate have been trialled (<xref ref-type="bibr" rid="bibr5-0004867412437346">APA, 2002</xref>; <xref ref-type="bibr" rid="bibr113-0004867412437346">Malhi et al., 2009d</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>).</p>
</caption>
<graphic xlink:href="10.1177_0004867412437346-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section26-0004867412437346">
<title>Specificity within BD</title>
<p>Lithium is particularly suited to the treatment of ‘classic’ (manic-depressive) bipolar disorder. Its specificity for presentations characterized by recognizable recurrent episodes of mania or depression with clearly established euthymia in between means that it is less suited to complex manifestations of bipolarity (<xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>; <xref ref-type="bibr" rid="bibr115-0004867412437346">Malhi et al., 2012</xref>). A corollary view, conceptualizing lithium response as a quality biomarker of core bipolarity, sheds an awkward light on the broader bipolar spectrum.</p>
</sec>
<sec id="section27-0004867412437346">
<title>Efficacy in other disorders</title>
<sec id="section28-0004867412437346">
<title>Major (unipolar) depression</title>
<p>Lithium is superior to placebo in the maintenance phase of unipolar depression (<xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>) and is effective in preventing relapse across a range of plasma levels (<xref ref-type="bibr" rid="bibr35-0004867412437346">Cipriani et al., 2006</xref>; <xref ref-type="bibr" rid="bibr75-0004867412437346">Hopkins and Gelenberg, 2000</xref>). Its efficacy has not been compared to other drugs in detail (<xref ref-type="bibr" rid="bibr35-0004867412437346">Cipriani et al., 2006</xref>; <xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>) and therefore conventional antidepressants are used first-line for the treatment of major depression with lithium added for augmentation (<xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>). In a naturalistic study that examined recurrences in patients with unipolar and bipolar depression, 59% of unipolar patients and 51% of bipolar patients had no recurrences in the 5 years after lithium prophylaxis was commenced, and 73.7% of the unipolar patients and 65.9% of bipolar patients reported a good outcome (<xref ref-type="bibr" rid="bibr95-0004867412437346">Lepkifker et al., 2007</xref>).</p>
</sec>
<sec id="section29-0004867412437346">
<title>Schizophrenia</title>
<p>The evidence for lithium use in schizophrenia is relatively weak with little impact on the core symptoms of the illness. Its principal therapeutic effect is on mood and it benefits those with affective and mood-related symptoms (<xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>; <xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>). This again points to its potential role as a biological probe.</p>
</sec>
</sec>
<sec id="section30-0004867412437346">
<title>Additional properties</title>
<sec id="section31-0004867412437346">
<title>Suicide / suicidal behaviour</title>
<p>Suicide is a significant contributor to increased mortality rates in BD (<xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>). The risk of suicide or suicide attempts in BD are about 10 times higher than in the general population (<xref ref-type="bibr" rid="bibr7-0004867412437346">Baldessarini et al., 2006</xref>) and so of the major benefits of long-term lithium therapy is its demonstrated ability to reduce the risk of suicide/suicidal behaviour (<xref ref-type="bibr" rid="bibr7-0004867412437346">Baldessarini et al., 2006</xref>; <xref ref-type="bibr" rid="bibr21-0004867412437346">Bowden, 2000</xref>; <xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>; <xref ref-type="bibr" rid="bibr67-0004867412437346">Goodwin et al., 2003</xref>; <xref ref-type="bibr" rid="bibr110-0004867412437346">Malhi et al., 2009a</xref>, <xref ref-type="bibr" rid="bibr112-0004867412437346">2009c</xref>) provided patients adhere to treatment (<xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>). In patients, the risk of suicide is six times greater for those not taking lithium as compared to those who are (<xref ref-type="bibr" rid="bibr7-0004867412437346">Baldessarini et al., 2006</xref>) and, therefore, clinically, lithium reduces the risk of death and suicide by 60% and the risk of self-harm by 70% (<xref ref-type="bibr" rid="bibr36-0004867412437346">Cipriani et al., 2005</xref>; <xref ref-type="bibr" rid="bibr67-0004867412437346">Goodwin et al., 2003</xref>). Further, patients who do not respond well to lithium prophylaxis in terms of relapse are still less likely to attempt suicide (<xref ref-type="bibr" rid="bibr127-0004867412437346">Muller-Oerlinghausen, 2001</xref>). This unique ‘anti-suicidal action’ of lithium remains an enigma, though it has been postulated that lithium targets impulsivity and aggression, both of which are thought to play a role in acts of suicide and self-harm (<xref ref-type="bibr" rid="bibr7-0004867412437346">Baldessarini et al., 2006</xref>; <xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>; <xref ref-type="bibr" rid="bibr186-0004867412437346">Young and Hammond, 2007</xref>).</p>
</sec>
<sec id="section32-0004867412437346">
<title>Neuroprotective effects</title>
<p>As previously discussed, while it is not known exactly how lithium exerts its therapeutic effects, its actions on neurotransmitter release and cellular signalling cascades, promote neuronal viability by protecting them against neurotoxicity and apoptosis (<xref ref-type="bibr" rid="bibr14-0004867412437346">Berk, 2009</xref>; <xref ref-type="bibr" rid="bibr18-0004867412437346">Berk et al., 2011b</xref>; <xref ref-type="bibr" rid="bibr143-0004867412437346">Post et al., 2003</xref>). The presence of increased neural glutamate (as found in mania) activates NMDA receptors and this produces excitatory neurotoxicity. Lithium protects against this process by inactivating these receptors in cultures of rat cerebellar granule cells (<xref ref-type="bibr" rid="bibr132-0004867412437346">Nonaka et al., 1998</xref>). Lithium also increases the release of the inhibitory neurotransmitter, GABA, which mediates a reduction of excitatory neurotransmission and potentially prevents neurotoxicity and cell death (<xref ref-type="bibr" rid="bibr24-0004867412437346">Brunello and Tascedda, 2003</xref>; <xref ref-type="bibr" rid="bibr44-0004867412437346">Dixon and Hokin, 1998</xref>; <xref ref-type="bibr" rid="bibr94-0004867412437346">Lenox et al., 1998</xref>; <xref ref-type="bibr" rid="bibr143-0004867412437346">Post et al., 2003</xref>). In addition, lithium treatment increases neuroprotective proteins such as BDNF and Bcl-2, and decreases pro-apoptotic enzymes such as GSK-3. Together, these changes to cellular metabolism, neurotransmitters and factors not only prevent cell death, but over the long term produce changes that increase neurotrophy and alter gene transcription (<xref ref-type="bibr" rid="bibr78-0004867412437346">Ikonomov and Manji, 1999</xref>; <xref ref-type="bibr" rid="bibr103-0004867412437346">Machado-Vieira et al., 2009b</xref>; <xref ref-type="bibr" rid="bibr124-0004867412437346">Marmol, 2008</xref>). Interestingly, <italic>N</italic>-acetyl-aspartate (NAA), a maker of neuronal function and viability, has been found to be increased at therapeutic levels of lithium (<xref ref-type="bibr" rid="bibr124-0004867412437346">Marmol, 2008</xref>).</p>
<p>Evidence for neuroprotection also comes from neurostructural findings that show increased grey matter volumes in lithium-treated bipolar patients compared to those not treated (<xref ref-type="bibr" rid="bibr103-0004867412437346">Machado-Vieira et al., 2009b</xref>). Of note, BD patients treated with lithium have larger hippocampal and amygdala volumes than healthy controls and those patients not on lithium therapy (<xref ref-type="bibr" rid="bibr73-0004867412437346">Hallahan et al., 2011</xref>). Further, one study has shown that the efficacy of prophylactic treatment is related to executive function such that excellent lithium responders have better executive function than poor, or non-lithium responders. In addition, lithium may also reduce the risk of dementia (<xref ref-type="bibr" rid="bibr85-0004867412437346">Kessing et al., 2010</xref>). The putative neuroprotective effects of lithium clearly warrant further investigation (<xref ref-type="bibr" rid="bibr148-0004867412437346">Rybakowski et al., 2009</xref>).</p>
</sec>
</sec>
<sec id="section33-0004867412437346">
<title>Tolerability</title>
<sec id="section34-0004867412437346">
<title>Side effects</title>
<p>Lithium is associated with both acute and chronic side effects that can limit tolerability but, in practice, for the majority of patients the impact of these is transient and modest (<xref ref-type="bibr" rid="bibr107-0004867412437346">Malhi and Berk, 2012</xref>).</p>
</sec>
<sec id="section35-0004867412437346">
<title>Acute</title>
<p>Upon initiating lithium, side effects such as tremor, general fatigue, diarrhoea, thirst, polyuria, nausea, headache and vomiting are common but the effects are usually transient (<xref ref-type="table" rid="table1-0004867412437346">Table 1</xref>) (<xref ref-type="bibr" rid="bibr60-0004867412437346">Fyro et al., 1970</xref>; <xref ref-type="bibr" rid="bibr101-0004867412437346">Lydiard and Gelenberg, 1982</xref>) and usually last no more than a day or so, but in some patients troublesome side effects can persist for days or weeks (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>). The majority of these side effects are associated with rapid increases of plasma lithium concentration and therefore can also occur when the dose of lithium is raised (<xref ref-type="bibr" rid="bibr60-0004867412437346">Fyro et al., 1970</xref>; <xref ref-type="bibr" rid="bibr82-0004867412437346">Karniol et al., 1978</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>).</p>
<table-wrap id="table1-0004867412437346" position="float">
<label>Table 1.</label>
<caption>
<p>Transient and acute side effects of lithium therapy.</p>
</caption>
<graphic alternate-form-of="table1-0004867412437346" xlink:href="10.1177_0004867412437346-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Transient</td>
<td>Nausea, vomiting and diarrhoea</td>
</tr>
<tr>
<td>Tiredness</td>
<td>Fatigue and lethargy</td>
</tr>
<tr>
<td>Tremor</td>
<td>Resting and peripheral</td>
</tr>
<tr>
<td>Thirst</td>
<td>Polydipsia and polyuria</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section36-0004867412437346">
<title>Chronic</title>
<p>In the management of BD, lithium is usually prescribed long term and therefore chronic side effects may emerge following years and decades of treatment.</p>
</sec>
<sec id="section37-0004867412437346">
<title>Renal</title>
<p>Long-term treatment with lithium can impair the renal concentrating ability and cause polyuria and secondary thirst (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr150-0004867412437346">Schou and Vestergaard, 1988</xref>). In most cases this effect is modest and renal function is readily restored upon cessation of lithium but in a minority of patients chronic lithium use induces renal insufficiency. The precise mechanism by which this occurs is not known but it warrants careful monitoring as it can potentially lead to end-stage renal failure (<xref ref-type="bibr" rid="bibr10-0004867412437346">Bendz, 1983</xref>; <xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr123-0004867412437346">Markowitz et al., 2000</xref>). There is a relatively small risk of renal toxicity with long-term lithium use. Specifically, end-stage renal failure occurs in 0.53% of lithium-treated individuals compared to 0.2% in the general population (<xref ref-type="bibr" rid="bibr40-0004867412437346">Coresh et al., 2003</xref>) but it is important to note that in the vast majority of bipolar patients the trajectory of decrease in glomerular function with long-term lithium treatment is similar to that associated with normal ageing (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>). Further, the risks for renal disease such as diabetes are generally more common in bipolar cohorts, and changes may not emerge solely because of lithium use. (See <xref ref-type="table" rid="table2-0004867412437346">Table 2</xref> for renal monitoring recommendations.)</p>
<table-wrap id="table2-0004867412437346" position="float">
<label>Table 2.</label>
<caption>
<p>Lithium therapy monitoring recommendations.</p>
</caption>
<graphic alternate-form-of="table2-0004867412437346" xlink:href="10.1177_0004867412437346-table2.tif"/>
</table-wrap>
</sec>
<sec id="section38-0004867412437346">
<title>Endocrine</title>
<p>Lithium affects both thyroid and parathyroid gland functioning. In the thyroid gland its accumulation alters the stimulation of thyroglobulin and inhibits iodine uptake, iodotyrosine coupling and thyroxine secretion. Reduction of the latter leads to an increase in TSH and the typical clinical picture of hypothyroidism emerges (<xref ref-type="bibr" rid="bibr100-0004867412437346">Lombardi et al., 1993</xref>). Clinically significant hypothyroidism is seen in 8–19% of patients on lithium, as compared to 0.5–1% in the general population (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr81-0004867412437346">Johnston and Eagles, 1999</xref>), especially in women and the elderly and more so within the first 2 years of commencing treatment (<xref ref-type="bibr" rid="bibr175-0004867412437346">Vincent et al., 1993</xref>). However, even independent of treatment, thyroid abnormalities are more common in bipolar disorder (<xref ref-type="bibr" rid="bibr29-0004867412437346">Chakrabarti, 2011</xref>). The detection and management of hypothyroidism is important because it increases the likelihood of developing depression and rapid cycling (<xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>; <xref ref-type="bibr" rid="bibr175-0004867412437346">Vincent et al., 1993</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>) and therefore patients with hypothyroidism on lithium therapy should be prescribed thyroxine (<xref ref-type="bibr" rid="bibr58-0004867412437346">Freeman and Freeman, 2006</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>).</p>
<p>Patients on lithium are prone to develop hypercalcaemia secondary to elevated parathyroid hormone (PTH) levels. This occurs because lithium decreases PTH calcitonin binding (<xref ref-type="bibr" rid="bibr92-0004867412437346">Kusalic and Engelsmann, 1999</xref>) which results in a compensatory decrease in urinary calcium excretion and is associated with a decrease in bone resorption (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr105-0004867412437346">Mak et al., 1998</xref>).</p>
<p>Both thyroid and parathyroid abnormalities are relatively common with long-term lithium therapy and therefore both thyroid function and blood calcium levels warrant routine assessment (see <xref ref-type="table" rid="table2-0004867412437346">Table 2</xref>).</p>
</sec>
<sec id="section39-0004867412437346">
<title>Obesity</title>
<p>Long-term treatment with lithium usually results in noticeable weight gain. An increase of 1–2 kg over the first 12 weeks of treatment is common and in some individuals this increase may continue. Overall, 5% or more of patients on lithium (<xref ref-type="bibr" rid="bibr84-0004867412437346">Keck et al., 2003</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>) report noticeable weight gain but this is modest in comparison to other psychotropic medications (<xref ref-type="bibr" rid="bibr3-0004867412437346">Allison et al., 1999</xref>; <xref ref-type="bibr" rid="bibr84-0004867412437346">Keck et al., 2003</xref>).</p>
<p>BD predisposes to obesity because of hypersomnia, hyperphagia and decreased physical activity, especially when patients are depressed. Treatment with lithium adds to this by virtue of its direct effects on appetite, thyroid function and cellular glucose uptake, all of which encourage weight gain (<xref ref-type="bibr" rid="bibr84-0004867412437346">Keck et al., 2003</xref>). Compounding this further, patients on lithium often experience polydipsia and consume drinks with high sugar and calorie content (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr97-0004867412437346">Livingstone and Rampes, 2006</xref>). Therefore, when commencing lithium it is important to anticipate weight gain (see <xref ref-type="table" rid="table2-0004867412437346">Table 2</xref>) and to put in place preventative lifestyle changes that include diet and exercise.</p>
</sec>
<sec id="section40-0004867412437346">
<title>Cardiac</title>
<p>Patients on long-term lithium therapy may manifest electrocardiogram (ECG) changes such as QTc interval prolongation, increased PR interval duration, diffuse T-wave inversion and sinus bradycardia (<xref ref-type="bibr" rid="bibr76-0004867412437346">Hsu et al., 2005</xref>; <xref ref-type="bibr" rid="bibr144-0004867412437346">Roose et al., 1979</xref>; <xref ref-type="bibr" rid="bibr146-0004867412437346">Rosenqvist et al., 1993</xref>; <xref ref-type="bibr" rid="bibr163-0004867412437346">Steckler, 1994</xref>; <xref ref-type="bibr" rid="bibr167-0004867412437346">Timmer and Sands, 1999</xref>). Most of these changes are reversible and disappear when lithium is withdrawn, but occasionally cardiac abnormalities can persist, and rarely may precipitate clinically significant arrhythmias (<xref ref-type="bibr" rid="bibr120-0004867412437346">Mamiya et al., 2005</xref>; <xref ref-type="bibr" rid="bibr146-0004867412437346">Rosenqvist et al., 1993</xref>).</p>
</sec>
<sec id="section41-0004867412437346">
<title>Neurological</title>
<p>The neurotoxic effects of lithium are related to treatment duration (<xref ref-type="bibr" rid="bibr133-0004867412437346">Oakley et al., 2001</xref>). A reduction in peripheral nerve conduction velocities (<xref ref-type="bibr" rid="bibr30-0004867412437346">Chang et al., 1990</xref>) results in neurological symptoms and the central effects can be observed on electroencephalography (EEG) (<xref ref-type="bibr" rid="bibr57-0004867412437346">Fountoulakis et al., 2008b</xref>). Clinically, the effects of lithium manifest as tremor and changes in cognition (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr91-0004867412437346">Kropf and Muller-Oerlinghausen, 1979</xref>; <xref ref-type="bibr" rid="bibr162-0004867412437346">Squire et al., 1980</xref>; <xref ref-type="bibr" rid="bibr180-0004867412437346">Wingo et al., 2009</xref>).</p>
</sec>
<sec id="section42-0004867412437346">
<title>Tremor</title>
<p>Tremor is a relatively common and troubling side effect of lithium therapy that can sometimes persist long term (<xref ref-type="bibr" rid="bibr101-0004867412437346">Lydiard and Gelenberg, 1982</xref>). It occurs at therapeutic levels and can therefore be treated by reducing the dose of lithium or administering beta-blockers (<xref ref-type="bibr" rid="bibr26-0004867412437346">Carroll et al., 1987</xref>; <xref ref-type="bibr" rid="bibr83-0004867412437346">Kato et al., 1996</xref>; <xref ref-type="bibr" rid="bibr171-0004867412437346">Vestergaard et al., 1988</xref>).</p>
</sec>
<sec id="section43-0004867412437346">
<title>Cognition</title>
<p>The effects of lithium on cognition are disputed with short-term studies in healthy subjects finding no discernible effects (<xref ref-type="bibr" rid="bibr82-0004867412437346">Karniol et al., 1978</xref>; <xref ref-type="bibr" rid="bibr91-0004867412437346">Kropf and Muller-Oerlinghausen, 1979</xref>) but long-term exposure seemingly producing changes in learning and memory (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr91-0004867412437346">Kropf and Muller-Oerlinghausen, 1979</xref>; <xref ref-type="bibr" rid="bibr162-0004867412437346">Squire et al., 1980</xref>; <xref ref-type="bibr" rid="bibr180-0004867412437346">Wingo et al., 2009</xref>). Others have suggested that cognition is preserved in lithium responders (<xref ref-type="bibr" rid="bibr147-0004867412437346">Rybakowski and Suwalska, 2010</xref>) and clearly this warrants further research.</p>
</sec>
</sec>
<sec id="section44-0004867412437346">
<title>Toxicity</title>
<sec id="section45-0004867412437346">
<title>Acute</title>
<p>In acute intoxication the plasma levels of lithium can reach potentially lethal levels (&gt; 2.0 mmol/L), especially once lithium excretion reaches its upper limit, after which it accumulates rapidly and leads to precipitous worsening of symptoms (<xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>). However, in some instances, even such high plasma levels may lead to relatively mild symptoms, and individuals recover without permanent neurological damage (<xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>). This is because lithium can take up to 24 hours to cross the blood–brain barrier into the brain. In counterpoint, elderly individuals can manifest lithium toxicity at therapeutic levels (<xref ref-type="bibr" rid="bibr157-0004867412437346">Shulman, 2010</xref>) and therefore it is essential to monitor plasma lithium levels closely and avoid toxicity but, if it occurs, prompt action may still prevent serious damage.</p>
</sec>
<sec id="section46-0004867412437346">
<title>Chronic</title>
<p>If lithium is found to be effective and the individual is well suited to lithium therapy, it is usually administered for years and sometimes decades to maintain mood stability and prevent the recurrence of symptoms (see previous discussion on ‘Maintenance and prophylaxis’). However, with life-long treatment lithium can gradually accumulate within the brain and lead to chronic toxicity. This occurs despite plasma concentrations remaining within the therapeutic range because lithium has a longer half-life in brain tissue than in plasma (<xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>). Toxicity because of chronic lithium use is also subject to other factors including change in lithium dose, individual tolerance and impaired renal function, especially in aging individuals (<xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>; <xref ref-type="bibr" rid="bibr70-0004867412437346">Grandjean and Aubry, 2009b</xref>; <xref ref-type="bibr" rid="bibr133-0004867412437346">Oakley et al., 2001</xref>). Therefore, it is important to routinely consider the possibility of chronic toxicity in patients being prescribed lithium long term.</p>
</sec>
<sec id="section47-0004867412437346">
<title>Treatment</title>
<p>In a recent study (<xref ref-type="bibr" rid="bibr48-0004867412437346">Eyer et al., 2006</xref>) that examined patients with chronic and acute on chronic lithium toxicity, haemodialysis was found to be the most effective method for reducing lithium in the blood, whereas diuretics were partially effective at increasing renal clearance. One limitation of this study, however, was that patients were also taking other medications known to alter renal function (<xref ref-type="bibr" rid="bibr48-0004867412437346">Eyer et al., 2006</xref>). Nevertheless, haemodialysis can be used to treat lithium toxicity and, in addition, thiazide diuretics, ACE inhibitors or non-steroidal anti-inflammatory medications may confer some prophylactic benefits and perhaps even prevent or limit the risk of renal dysfunction, or episodes of intoxication (<xref ref-type="bibr" rid="bibr53-0004867412437346">Finley et al., 1995</xref>; <xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr109-0004867412437346">Malhi and Tanious, 2011</xref>). In this regard, potassium (20–50 mmol/day) is also potentially useful in reducing the effects of lithium toxicity on the kidney (<xref ref-type="bibr" rid="bibr8-0004867412437346">Batlle et al., 1985</xref>; <xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>) and there is preclinical evidence (from animal studies) that <italic>N</italic>-acetyl cysteine may prevent lithium-induced renal harm (<xref ref-type="bibr" rid="bibr46-0004867412437346">Efrati et al., 2005</xref>).</p>
</sec>
</sec>
<sec id="section48-0004867412437346">
<title>Clinical application</title>
<sec id="section49-0004867412437346">
<title>Initiating therapy</title>
<p>Given that lithium has a relatively narrow therapeutic index, it is important to maintain lithium levels within a specific range for each individual patient. This requires achieving a balance between effectiveness and adverse effects. Earlier guidelines (<xref ref-type="fig" rid="fig3-0004867412437346">Figure 3</xref>) suggest that when initiating lithium therapy de novo it should be administered in small divided doses to minimise side effects, and then titrated gradually to achieve plasma levels of 0.5–1.2 mmol/L, while monitoring for tolerability (<xref ref-type="bibr" rid="bibr5-0004867412437346">American Psychiatric Association (APA), 2002</xref>). Further, lithium naïve patients should aim to achieve plasma levels of 0.8–1.0 mmol/L, especially for prophylaxis against manic episodes (<xref ref-type="bibr" rid="bibr75-0004867412437346">Hopkins and Gelenberg, 2000</xref>). The National Institute for Health and Clinical Excellence (<xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>) proposes a narrower starting dose of 0.6–0.8 mmol/L, and more recent studies indicate that these suggested levels confer reasonable prophylaxis and are associated with an acceptable side effect profile (<xref ref-type="bibr" rid="bibr154-0004867412437346">Severus et al., 2008</xref>).</p>
<fig id="fig3-0004867412437346" position="float">
<label>Figure 3.</label>
<caption>
<p>Recommended lithium levels for initiating treatment and prophylaxis (adapted from <xref ref-type="bibr" rid="bibr109-0004867412437346">Malhi and Tanious, 2011</xref>). The figure shows the recommended plasma lithium concentrations for initiation of treatment and prophylaxis in patients with BD (<xref ref-type="bibr" rid="bibr5-0004867412437346">APA, 2002</xref>; <xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>). [1] Recommendation is to start with low divided doses and increase to a plasma lithium concentration of 1.2 mmol/L depending on adverse effects; as concentrations reach this upper therapeutic range, the patient should be monitored and assessed for toxicity; [2] concentration range that may be sufficient for prophylaxis; [3] concentration range commonly chosen by psychiatrists but that has not been formally studied; [4] concentration range that is more efficacious for controlling symptoms, especially mania, although adverse effects are less well tolerated; [5] recommended concentration range for stabilizing patients; [6] recommended concentration range for patients previously taking lithium who have relapsed. (APA: American Psychiatric Association; CANMAT: Canadian Network for Mood and Anxiety Treatments; NICE: National Institute for Health and Clinical Excellence (UK).)</p>
</caption>
<graphic xlink:href="10.1177_0004867412437346-fig3.tif"/>
</fig>
<p>Therefore, clinically, after stabilizing the plasma levels of lithium to 0.6–0.8mmol/L, the oral dose can then be increased to achieve higher plasma levels if breakthrough symptoms occur (<xref ref-type="bibr" rid="bibr130-0004867412437346">NICE, 2006</xref>). It is this higher range of lithium plasma levels that the Canadian Network for Mood and Anxiety Treatments (CANMAT) guideline advocates for maintenance of BD with lithium therapy (<xref ref-type="bibr" rid="bibr182-0004867412437346">Yatham et al., 2006</xref>). The APA also suggests that higher plasma lithium levels (0.8–1.0 mmol/L) may be used for controlling symptoms but that relatively low levels (0.4–0.6 mmol/L) may provide sufficient prophylaxis long term (<xref ref-type="bibr" rid="bibr5-0004867412437346">APA, 2002</xref>; <xref ref-type="bibr" rid="bibr154-0004867412437346">Severus et al., 2008</xref>).</p>
</sec>
</sec>
<sec id="section50-0004867412437346">
<title>Maintenance therapy</title>
<sec id="section51-0004867412437346">
<title>Target lithium levels</title>
<p>The primary aim of maintenance therapy is to prevent the recurrence of symptoms whilst minimizing side effects and maintaining compliance. Interestingly, a review of different dosing schedules has demonstrated a dose–response relationship between lithium and the recurrence of symptoms wherein even low levels of lithium may be protective (<xref ref-type="bibr" rid="bibr75-0004867412437346">Hopkins and Gelenberg, 2000</xref>). However, the evidence for ‘high’ versus ‘low’ lithium levels in prophylaxis is inconsistent. Predictably, studies report both high rates of relapse with ‘low’ plasma lithium levels (0.4–0.6 mmol/L), presumably because of lack of efficacy, and low rates of relapse with ‘high’ levels (0.8–1.1 mmol/L), but contrary to this some studies have found that high plasma lithium levels result in greater dropouts because of adverse effects (<xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>). In either context, in clinical practice it is important to avoid the abrupt cessation of treatment with lithium, as this is likely to precipitate a relapse of the illness (<xref ref-type="bibr" rid="bibr121-0004867412437346">Mander and Loudon, 1988</xref>).</p>
<p>In sum, plasma lithium concentrations should be optimised to the individual symptom and tolerability profile of patients. BD patients likely to develop depressive episodes may benefit from prophylactic levels of 0.4–0.8 mmol/L, whereas in those more likely to develop mania, levels of 0.6–1.0 mmol/L may be more effective (<xref ref-type="bibr" rid="bibr90-0004867412437346">Kleindienst et al., 2005</xref>, <xref ref-type="bibr" rid="bibr89-0004867412437346">2007</xref>; <xref ref-type="bibr" rid="bibr153-0004867412437346">Severus et al., 2009</xref>). Equally, an individual with tolerability issues at a higher level may derive more benefit from low-dose lithium therapy.</p>
</sec>
<sec id="section52-0004867412437346">
<title>Administration</title>
<p>Most of the current recommendations for lithium administration suggest divided daily doses. One of the main arguments against a single-dose (SD) regime is that compared to a multiple-dose (MD) schedule, there are greater peaks in plasma lithium levels, which are not well tolerated because of associated side effects, and deeper troughs that make breakthrough symptoms more likely. However, since pharmacokinetic properties remain unchanged with either regime (<xref ref-type="bibr" rid="bibr138-0004867412437346">Perry et al., 1981</xref>), in practice, no clinically significant differences have been found with respect to side-effect profile and recurrence of mania (<xref ref-type="bibr" rid="bibr98-0004867412437346">Ljubicic et al., 2008</xref>). Further, plasma lithium levels remain within the therapeutic range with both SD and MD regimes (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr77-0004867412437346">Hunter, 1988</xref>; <xref ref-type="bibr" rid="bibr98-0004867412437346">Ljubicic et al., 2008</xref>), and because lithium exerts its therapeutic effects within the CNS there is another ‘buffer’ between plasma levels and therapeutic effect that needs to be considered when comparing dosing schedules. Specifically, lithium has a longer half-life in neural tissues and, therefore, lithium once-daily, or even every alternate day, may, in some cases, be sufficient to maintain an effective brain lithium concentration over a 48-hour period when used for prophylaxis, especially given the lag between plasma and brain level adjustment (<xref ref-type="bibr" rid="bibr98-0004867412437346">Ljubicic et al., 2008</xref>; <xref ref-type="bibr" rid="bibr141-0004867412437346">Plenge et al., 1994</xref>) (<xref ref-type="fig" rid="fig4-0004867412437346">Figure 4</xref>).</p>
<fig id="fig4-0004867412437346" position="float">
<label>Figure 4.</label>
<caption>
<p>Plasma and brain lithium levels. At therapeutic plasma lithium levels (0.8 mmol/L) the level of lithium in the brain is approximately 0.4 mmol/L (the ratio of brain:plasma lithium levels is approx 0.5:1) (Soares et al., 2000). Of note: lithium levels in the brain peak approximately 24 hours after they peak in plasma (<xref ref-type="bibr" rid="bibr32-0004867412437346">Chen et al., 2004</xref>).</p>
</caption>
<graphic xlink:href="10.1177_0004867412437346-fig4.tif"/>
</fig>
<p>An advantage of a daily schedule for lithium compared to a twice-daily schedule is that it causes less polyuria with long-term administration and hence decreases the chance of permanent renal damage (<xref ref-type="bibr" rid="bibr10-0004867412437346">Bendz, 1983</xref>; <xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>). In addition, since lithium clearance is lower overnight, a single evening dose can be reduced by 25% (<xref ref-type="bibr" rid="bibr98-0004867412437346">Ljubicic et al., 2008</xref>). Such a reduction in the oral dose of lithium significantly decreases the likelihood of side effects (<xref ref-type="bibr" rid="bibr39-0004867412437346">Coppen et al., 1983</xref>) and therefore, if in practice it is well tolerated, a once-daily trial should be considered (<xref ref-type="bibr" rid="bibr65-0004867412437346">Gitlin, 1999</xref>; <xref ref-type="bibr" rid="bibr98-0004867412437346">Ljubicic et al., 2008</xref>; <xref ref-type="bibr" rid="bibr109-0004867412437346">Malhi and Tanious, 2011</xref>).</p>
<p>Alternate-day dosing may further reduce side effects and the risk of renal damage. Early studies that maintained lithium levels within the therapeutic range showed promise, but recent research (<xref ref-type="bibr" rid="bibr79-0004867412437346">Jensen et al., 1990</xref>; <xref ref-type="bibr" rid="bibr140-0004867412437346">Plenge et al., 1999</xref>) suggests that alternate-day dosing confers a threefold increase in the risk of relapse as compared to daily dosing, and that plasma levels drop below 0.5 mmol/L. Further, from a practical perspective it is much harder to adhere to irregular medication regimes.</p>
<p>In sum, a once-daily dosing schedule confers several advantages. First, a low, single dose of lithium at night reduces the likelihood of peak side effects, such as fatigue and sedation (<xref ref-type="bibr" rid="bibr98-0004867412437346">Ljubicic et al., 2008</xref>). Second, reducing the oral dose diminishes the overall side-effect burden (<xref ref-type="bibr" rid="bibr23-0004867412437346">Bowen et al., 1991</xref>) and reduces the likelihood of glomerular impairment long term. Finally, daily dosing is advantageous because it enhances adherence and this is important in achieving long-term efficacy.</p>
</sec>
</sec>
<sec id="section53-0004867412437346">
<title>Adherence</title>
<p>Long-term maintenance of plasma lithium levels is critical for effective prophylaxis of BD. Continuity of maintenance treatment is particularly important because cessation is a strong predictor of suicide risk (<xref ref-type="bibr" rid="bibr186-0004867412437346">Young and Hammond, 2007</xref>) and is the main reason for recurrences</p>
<sec id="section54-0004867412437346">
<title>Reasons for poor adherence</title>
<p>The reasons for poor adherence are complex and varied. Side effects are a commonly cited reason that can be quite incapacitating. However, tolerability is not the major driver of adherence; indeed, stigma and a lack of acceptance and understanding play a significant role. Commonly reported side effects of lithium therapy that impair compliance include weight gain, polyuria, tremor and fatigue (<xref ref-type="bibr" rid="bibr145-0004867412437346">Rosa et al., 2007</xref>). Weight gain is troublesome, in particular for females (<xref ref-type="bibr" rid="bibr49-0004867412437346">Fakhoury et al., 2001</xref>; <xref ref-type="bibr" rid="bibr86-0004867412437346">Kessing et al., 2007</xref>; <xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>) and, not surprisingly, individuals who report multiple side effects are also more likely to be less satisfied with their medication and management overall (<xref ref-type="bibr" rid="bibr49-0004867412437346">Fakhoury et al., 2001</xref>). <xref ref-type="fig" rid="fig5-0004867412437346">Figure 5</xref> attempts to depict graphically the relationship between treatment adherence, risk of relapse and plasma lithium levels.</p>
<fig id="fig5-0004867412437346" position="float">
<label>Figure 5.</label>
<caption>
<p>Treatment adherence and risk of relapse. A: (BLUE) Low plasma lithium levels produce better treatment adherence, but the risk of relapse is high because low lithium levels often provide insufficient prophylaxis; B: (GREEN) this range of lithium plasma levels is optimal as it achieves prophylaxis and the risk of relapse is low; C: (RED) high plasma lithium levels result in poor treatment adherence because the likelihood of troublesome side effects is greater. Clinically, intermittent adherence is the most common form of non-adherence and this means that lithium levels are often fluctuating and prophylaxis is suboptimal.</p>
</caption>
<graphic xlink:href="10.1177_0004867412437346-fig5.tif"/>
</fig>
<p>In addition to tolerability issues, individuals taking lithium also express frustration about needing to take medications when they are symptom-free. This is associated with denial of their illness and it contributes to a perceived lack of efficacy and loss of energy and productivity. Further, some patients report missing the ‘highs’ of hypomania (<xref ref-type="bibr" rid="bibr69-0004867412437346">Grandjean and Aubry, 2009a</xref>; <xref ref-type="bibr" rid="bibr116-0004867412437346">Malhi et al., 2010</xref>; <xref ref-type="bibr" rid="bibr145-0004867412437346">Rosa et al., 2007</xref>; <xref ref-type="bibr" rid="bibr151-0004867412437346">Scott and Pope, 2002</xref>). All of these issues are more evident in those who have been recently diagnosed with BD, younger individuals and those taking lithium long term. Interestingly, individuals who do not have a strong doctor–patient alliance and those who have received less education about the disorder and its treatment are also likely to adhere to medication (<xref ref-type="bibr" rid="bibr88-0004867412437346">Kleindienst and Greil, 2004</xref>; <xref ref-type="bibr" rid="bibr145-0004867412437346">Rosa et al., 2007</xref>).</p>
</sec>
<sec id="section55-0004867412437346">
<title>Enhancing adherence</title>
<p>Enhancing adherence requires a multifaceted approach that involves education and monitoring in the context of a therapeutic alliance (<xref ref-type="bibr" rid="bibr16-0004867412437346">Berk et al., 2004</xref>, <xref ref-type="bibr" rid="bibr12-0004867412437346">2010a</xref>). It has been shown that patients who are informed about their illness and the importance of long-term treatment, have better compliance (<xref ref-type="bibr" rid="bibr38-0004867412437346">Colom et al., 2003</xref>; <xref ref-type="bibr" rid="bibr47-0004867412437346">Even et al., 2007</xref>). Other strategies that enhance adherence to treatment include educating the family and friends of the patient to recognise the early signs of relapse and institute suitable measures to curtail stressors (<xref ref-type="bibr" rid="bibr145-0004867412437346">Rosa et al., 2007</xref>; <xref ref-type="bibr" rid="bibr13-0004867412437346">Berk et al., 2011a</xref>). Further, encouraging patients to make a commitment to treatment prior to commencement (<xref ref-type="bibr" rid="bibr145-0004867412437346">Rosa et al., 2007</xref>; <xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>) and coupling pharmacotherapy with psychotherapy has been shown to greatly improve patient outcomes (<xref ref-type="bibr" rid="bibr38-0004867412437346">Colom et al., 2003</xref>; <xref ref-type="bibr" rid="bibr47-0004867412437346">Even et al., 2007</xref>; <xref ref-type="bibr" rid="bibr181-0004867412437346">Yatham et al., 2005</xref>).</p>
<p>The close monitoring of patients improves adherence in two ways. First, it allows tailoring of the therapeutic dose to suit the individual, so that therapeutic benefit is optimised and the likelihood of side effects is reduced (<xref ref-type="bibr" rid="bibr159-0004867412437346">Silverstone, 2000</xref>). Second, regular monitoring increases clinical contact and therefore patients are likely to receive more frequent supervision and better education concerning their illness and its management (<xref ref-type="bibr" rid="bibr145-0004867412437346">Rosa et al., 2007</xref>).</p>
</sec>
</sec>
<sec id="section56-0004867412437346">
<title>Individualising lithium therapy</title>
<p>Lithium is a suitable first-line treatment option in the management of BD that is particularly efficacious when applied selectively (<xref ref-type="bibr" rid="bibr15-0004867412437346">Berk and Malhi, 2011</xref>). As mentioned already, those with a classic picture of BD are most likely to be responsive, whereas those with mixed presentations, rapid cycling and less easily defined manifestations are likely to respond poorly (<xref ref-type="bibr" rid="bibr64-0004867412437346">Gershon et al., 2009</xref>).</p>
<p>Predictors of a poor response to lithium include comorbid substance misuse and a history of more than three episodes of a predominantly depressive presentation. A positive family history, administration early in the course of the illness and a beneficial prior response are predictors of a good response (<xref ref-type="bibr" rid="bibr59-0004867412437346">Frye et al., 1998</xref>). Using such indicators, amongst others, the application of lithium can be individualized. Further, as has been discussed in detail, the plasma levels of lithium can be monitored and adjusted according to mood state and the needs of the individual (<xref ref-type="bibr" rid="bibr119-0004867412437346">Malhi et al., 2011b</xref>). To assist with this, the lithiumeter can be used to determine the optimal plasma levels required from initiation through to maintenance, taking into consideration the predominant mood state (<xref ref-type="fig" rid="fig6-0004867412437346">Figure 6</xref>).</p>
<fig id="fig6-0004867412437346" position="float">
<label>Figure 6.</label>
<caption>
<p>The lithiumeter. The lithiumeter depicts <italic>indications</italic> and <italic>risks</italic> associated with lithium according to its blood plasma levels. Optimal levels for <italic>treatment initiation</italic> is between 0.6 and 0.8 mmol/L, and should be individually tailored on the basis of recurrences and polarity of symptoms. <italic>Indications</italic>: This depicts suitable plasma levels for initiation and maintenance therapy in relation to the phases of illness, which are shown on the left. Prophylaxis for depression (shown in blue) might be achieved satisfactorily at lower levels than for mania (shown in green). <italic>Risks</italic>: The risks associated with lithium therapy are illustrated on the right in red. Acute toxicity is likely at levels above 1.2 mmol/L but, over time, even much lower therapeutic levels of lithium can lead to chronic toxicity, especially in elderly individuals. However, relapse/recurrence is more likely at lower plasma lithium levels. Reproduced with permission from <xref ref-type="bibr" rid="bibr107-0004867412437346">Malhi and Berk (2012)</xref>.</p>
</caption>
<graphic xlink:href="10.1177_0004867412437346-fig6.tif"/>
</fig>
</sec>
</sec>
<sec id="section57-0004867412437346" sec-type="conclusions">
<title>Conclusion</title>
<p>Recent evidence (<xref ref-type="bibr" rid="bibr63-0004867412437346">Geddes et al., 2010</xref>; <xref ref-type="bibr" rid="bibr104-0004867412437346">McKnight et al., 2012</xref>) has once again positioned lithium centre stage in the management of BD. Used judiciously, the side effects of this magical element can be minimised and significant long-term efficacy can be achieved. Within the growing BD armamentarium, lithium is one of the few agents that not only offers effective management of the illness, but is also potentially anti-suicidal and neuroprotective. To gain full benefit, however, lithium has to be prescribed to specific patients at the correct dosage and in the appropriate manner. Thus, the practice of lithium therapy must be borne out of a sound understanding of its clinical science.</p>
</sec>
</body>
<back>
<sec id="section58-0004867412437346">
<title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="section59-0004867412437346">
<title>Declaration of interest</title>
<p>GSM has received research support from AstraZeneca, Eli Lilly, Organon, Pfizer, Servier and Wyeth; has been a speaker for AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; and has been a consultant for AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, and, Servier. MB has received research support from the Medical Benefits Fund of Australia, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi-Synthelabo, Servier, Solvay, and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, and Servier.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agam</surname><given-names>G</given-names></name>
<name><surname>Bersudsky</surname><given-names>Y</given-names></name>
<name><surname>Berry</surname><given-names>GT</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Knockout mice in understanding the mechanism of action of lithium</article-title>. <source>Biochemical Society Transactions</source> <volume>37</volume>: <fpage>1121</fpage>–<lpage>1125</lpage>.</citation>
</ref>
<ref id="bibr2-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alda</surname><given-names>M</given-names></name>
<name><surname>Hajek</surname><given-names>T</given-names></name>
<name><surname>Calkin</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Treatment of bipolar disorder: new perspectives</article-title>. <source>Annals of Medicine</source> <volume>41</volume>: <fpage>186</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr3-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allison</surname><given-names>DB</given-names></name>
<name><surname>Mentore</surname><given-names>JL</given-names></name>
<name><surname>Heo</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Antipsychotic-induced weight gain: a comprehensive research synthesis [see comment]</article-title>. <source>The American Journal of Psychiatry</source> <volume>156</volume>: <fpage>1686</fpage>–<lpage>1696</lpage>.</citation>
</ref>
<ref id="bibr4-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Altamura</surname><given-names>AC</given-names></name>
<name><surname>Gomeni</surname><given-names>R</given-names></name>
<name><surname>Sacchetti</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>1977</year>) <article-title>Plasma and intracellular kinetics of lithium after oral administration of various lithium salts</article-title>. <source>European Journal of Clinical Pharmacology</source> <volume>12</volume>: <fpage>59</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr5-0004867412437346">
<citation citation-type="journal">
<collab>American Psychiatric Association</collab> (<year>2002</year>) <article-title>Practice guideline for the treatment of patients with bipolar disorder (revision)</article-title>. <source>The American Journal of Psychiatry</source> <volume>159</volume>: <fpage>1</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr6-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baldessarini</surname><given-names>RJ</given-names></name>
<name><surname>Tondo</surname><given-names>L</given-names></name>
</person-group> (<year>2000</year>) <article-title>Does lithium treatment still work? Evidence of stable responses over three decades</article-title>. <source>Archives of General Psychiatry</source> <volume>57</volume>: <fpage>187</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr7-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baldessarini</surname><given-names>RJ</given-names></name>
<name><surname>Tondo</surname><given-names>L</given-names></name>
<name><surname>Davis</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review [see comment] [erratum appears in <italic>Bipolar Disord</italic> 2007; 9: 314]</article-title>. <source>Bipolar Disorders</source> <volume>8</volume>: <fpage>625</fpage>–<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr8-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batlle</surname><given-names>DC</given-names></name>
<name><surname>von Riotte</surname><given-names>AB</given-names></name>
<name><surname>Gaviria</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>1985</year>) <article-title>Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy</article-title>. <source>New England Journal of Medicine</source> <volume>312</volume>: <fpage>408</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr9-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>M</given-names></name>
<name><surname>Goetz</surname><given-names>T</given-names></name>
<name><surname>Glenn</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>The thyroid–brain interaction in thyroid disorders and mood disorders</article-title>. <source>Journal of Neuroendocrinology</source> <volume>20</volume>: <fpage>1101</fpage>–<lpage>1114</lpage>.</citation>
</ref>
<ref id="bibr10-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bendz</surname><given-names>H</given-names></name>
</person-group> (<year>1983</year>) <article-title>Kidney function in lithium-treated patients</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>68</volume>: <fpage>303</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr11-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bendz</surname><given-names>H</given-names></name>
<name><surname>Aurell</surname><given-names>M</given-names></name>
</person-group> (<year>1999</year>) <article-title>Drug-induced diabetes insipidus: incidence, prevention and management</article-title>. <source>Drug Safety</source> <volume>21</volume>: <fpage>449</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr12-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>L</given-names></name>
<name><surname>Hallam</surname><given-names>KT</given-names></name>
<name><surname>Colom</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>Enhancing medication adherence in patients with bipolar disorder</article-title>. <source>Human Psychopharmacology: Clinical and Experimental</source> <volume>25</volume>: <fpage>1</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr13-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>L</given-names></name>
<name><surname>Jorm</surname><given-names>AF</given-names></name>
<name><surname>Kelly</surname><given-names>CM</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>Development of guidelines for caregivers of people with bipolar disorder: a Delphi expert consensus study</article-title>. <source>Bipolar Disorders</source> <volume>13</volume>: <fpage>556</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr14-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
</person-group> (<year>2009</year>) <article-title>Neuroprogression: pathways to progressive brain changes in bipolar disorder</article-title>. <source>International Journal of Neuropsychopharmacology</source> <volume>12</volume>: <fpage>441</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr15-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Malhi</surname><given-names>GS</given-names></name>
</person-group> (<year>2011</year>) <article-title>Should antipsychotics take pole position in mania treatment?</article-title> <source>The Lancet</source> <volume>378</volume>: <fpage>1279</fpage>–<lpage>1281</lpage>.</citation>
</ref>
<ref id="bibr16-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Berk</surname><given-names>L</given-names></name>
<name><surname>Castle</surname><given-names>D</given-names></name>
</person-group> (<year>2004</year>) <article-title>A collaborative approach to the treatment alliance in bipolar disorder</article-title>. <source>Bipolar Disorders</source> <volume>6</volume>: <fpage>504</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr17-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Conus</surname><given-names>P</given-names></name>
<name><surname>Kapczinski</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>From neuroprogression to neuroprotection: implications for clinical care</article-title>. <source>The Medical Journal of Australia</source> <volume>193</volume>: <fpage>S36</fpage>–<lpage>S40</lpage>.</citation>
</ref>
<ref id="bibr18-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Kapczinski</surname><given-names>F</given-names></name>
<name><surname>Andreazza</surname><given-names>AC</given-names></name><etal/>
</person-group>. (<year>2011b</year>) <article-title>Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>35</volume>: <fpage>804</fpage>–<lpage>817</lpage>.</citation>
</ref>
<ref id="bibr19-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhagwagar</surname><given-names>Z</given-names></name>
<name><surname>Goodwin</surname><given-names>GM</given-names></name>
</person-group> (<year>2002</year>) <article-title>The role of lithium in the treatment of bipolar depression</article-title>. <source>Clinical Neuroscience Research</source> <volume>2</volume>: <fpage>222</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr20-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boton</surname><given-names>R</given-names></name>
<name><surname>Gaviria</surname><given-names>M</given-names></name>
<name><surname>Batlle</surname><given-names>DC</given-names></name>
</person-group> (<year>1987</year>) <article-title>Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy</article-title>. <source>American Journal of Kidney Diseases</source> <volume>10</volume>: <fpage>329</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr21-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bowden</surname><given-names>CL</given-names></name>
</person-group> (<year>2000</year>) <article-title>The ability of lithium and other mood stabilisers to decrease suicide risk and prevent relapse</article-title>. <source>Current Psychiatric Reports</source> <volume>2</volume>: <fpage>490</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr22-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bowden</surname><given-names>CL</given-names></name>
<name><surname>Mosolov</surname><given-names>S</given-names></name>
<name><surname>Hranov</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial</article-title>. <source>International Clinical Psychopharmacology</source> <volume>25</volume>: <fpage>60</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr23-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bowen</surname><given-names>RC</given-names></name>
<name><surname>Grof</surname><given-names>P</given-names></name>
<name><surname>Grof</surname><given-names>E</given-names></name>
</person-group> (<year>1991</year>) <article-title>Less frequent lithium administration and lower urine volume</article-title>. <source>The American Journal of Psychiatry</source> <volume>148</volume>: <fpage>189</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr24-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunello</surname><given-names>N</given-names></name>
<name><surname>Tascedda</surname><given-names>F</given-names></name>
</person-group> (<year>2003</year>) <article-title>Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders</article-title>. <source>International Journal of Neuropsychopharmacology</source> <volume>6</volume>: <fpage>181</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr25-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cade</surname><given-names>JFJ</given-names></name>
</person-group> (<year>1949</year>) <article-title>Lithium salts in the treatment of psychotic excitement</article-title>. <source>The Medical Journal of Australia</source> <volume>2</volume>: <fpage>349</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr26-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carroll</surname><given-names>JA</given-names></name>
<name><surname>Jefferson</surname><given-names>JW</given-names></name>
<name><surname>Greist</surname><given-names>JH</given-names></name>
</person-group> (<year>1987</year>) <article-title>Treating tremor induced by lithium</article-title>. <source>Hospital and Community Psychiatry</source> <volume>38</volume>: <fpage>1280</fpage>.</citation>
</ref>
<ref id="bibr27-0004867412437346">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Carson</surname><given-names>S</given-names></name>
<name><surname>Roberts</surname><given-names>S</given-names></name>
</person-group> (<year>2001</year>) <article-title>Lithium</article-title>. In: <person-group person-group-type="editor">
<name><surname>Murphy</surname><given-names>J</given-names></name>
</person-group> (ed) <source>Clinical Pharmacokinetics</source>. <edition>2nd edition.</edition> <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>American Society of Health System Pharmacists</publisher-name>, pp.<fpage>229</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr28-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cavanagh</surname><given-names>J</given-names></name>
<name><surname>Smyth</surname><given-names>R</given-names></name>
<name><surname>Goodwin</surname><given-names>GM</given-names></name>
</person-group> (<year>2004</year>) <article-title>Relapse into mania or depression following lithium discontinuation: a 7-year follow-up</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>109</volume>: <fpage>91</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr29-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chakrabarti</surname><given-names>S</given-names></name>
</person-group> (<year>2011</year>) <article-title>Thyroid functions and bipolar affective disorder</article-title>. <source>Journal of Thyroid Research</source> <year>2011</year>: <comment>306367</comment>, <fpage>13</fpage> pages.</citation>
</ref>
<ref id="bibr30-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>YC</given-names></name>
<name><surname>Lin</surname><given-names>HN</given-names></name>
<name><surname>Deng</surname><given-names>HC</given-names></name>
</person-group> (<year>1990</year>) <article-title>Subclinical lithium neurotoxicity: correlation of neural conduction abnormalities and serum lithium level in manic-depressive patients with lithium treatment</article-title>. <source>Acta Neurologica Scandinavica</source> <volume>82</volume>: <fpage>82</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr31-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Lennox</surname><given-names>B</given-names></name>
<name><surname>Jacob</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Explicit and implicit facial affect recognition in manic and depressed states of bipolar disorder: a functional magnetic resonance imaging study</article-title>. <source>Biological Psychiatry</source> <volume>59</volume>: <fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr32-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>KP</given-names></name>
<name><surname>Shen</surname><given-names>WW</given-names></name>
<name><surname>Lu</surname><given-names>ML</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Implication of serum concentration monitoring in patients with lithium intoxication</article-title>. <source>Psychiatry and Clinical Neurosciences</source> <volume>58</volume>: <fpage>25</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr33-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>ST</given-names></name>
<name><surname>Altshuler</surname><given-names>LL</given-names></name>
<name><surname>Melnyk</surname><given-names>KA</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>60</volume>: <fpage>181</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr34-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chiu</surname><given-names>C-T</given-names></name>
<name><surname>Chuang</surname><given-names>D-M</given-names></name>
</person-group> (<year>2010</year>) <article-title>Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders</article-title>. <source>Pharmacology and Therapeutics</source> <volume>128</volume>: <fpage>281</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr35-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Burgess</surname><given-names>S</given-names></name>
<name><surname>Carney</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Lithium versus antidepressants in the long-term treatment of unipolar affective disorder (Review)</article-title>. <source>Cochrane Database of Systematic Reviews</source> <volume>4</volume>: <fpage>CD003492</fpage>.</citation>
</ref>
<ref id="bibr36-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Pretty</surname><given-names>H</given-names></name>
<name><surname>Hawton</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials [see comment]</article-title>. <source>The American Journal of Psychiatry</source> <volume>162</volume>: <fpage>1805</fpage>–<lpage>1819</lpage>.</citation>
</ref>
<ref id="bibr37-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>LS</given-names></name>
<name><surname>Friedman</surname><given-names>JM</given-names></name>
<name><surname>Jefferson</surname><given-names>JW</given-names></name><etal/>
</person-group>. (<year>1994</year>) <article-title>A reevaluation of risk of in utero exposure to lithium [see comment] [erratum appears in <italic>JAMA</italic> 1994; 271: 1485]</article-title>. <source>The Journal of the American Medical Association</source> <volume>271</volume>: <fpage>146</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr38-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colom</surname><given-names>F</given-names></name>
<name><surname>Vieta</surname><given-names>E</given-names></name>
<name><surname>Martinez-Aran</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission</article-title>. <source>Archives of General Psychiatry</source> <volume>60</volume>: <fpage>402</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr39-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coppen</surname><given-names>A</given-names></name>
<name><surname>Abou-Saleh</surname><given-names>M</given-names></name>
<name><surname>Millin</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>1983</year>) <article-title>Decreasing lithium dosage reduces morbitidy and side-effects during prophylaxis</article-title>. <source>Journal of Affective Disorders</source> <volume>5</volume>: <fpage>353</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr40-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coresh</surname><given-names>J</given-names></name>
<name><surname>Astor</surname><given-names>B</given-names></name>
<name><surname>Greene</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey</article-title>. <source>American Journal of Kidney Diseases</source> <volume>41</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr41-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coryell</surname><given-names>W</given-names></name>
</person-group> (<year>2005</year>) <article-title>Rapid cycling bipolar disorder: clinical characteristics and treatment options</article-title>. <source>CNS Drugs</source> <volume>19</volume>: <fpage>557</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr42-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coryell</surname><given-names>W</given-names></name>
</person-group> (<year>2009</year>) <article-title>Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice</article-title>. <source>Bipolar Disorders</source> <volume>11</volume>: <fpage>77</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr43-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deranieh</surname><given-names>RM</given-names></name>
<name><surname>Greenberg</surname><given-names>ML</given-names></name>
</person-group> (<year>2009</year>) <article-title>Cellular consequences of inositol depletion</article-title>. <source>Biochemical Society Transactions</source> <volume>37</volume>: <fpage>1099</fpage>–<lpage>1103</lpage>.</citation>
</ref>
<ref id="bibr44-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dixon</surname><given-names>JF</given-names></name>
<name><surname>Hokin</surname><given-names>LE</given-names></name>
</person-group> (<year>1998</year>) <article-title>Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>95</volume>: <fpage>8363</fpage>–<lpage>8368</lpage>.</citation>
</ref>
<ref id="bibr45-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eastham</surname><given-names>JH</given-names></name>
<name><surname>Jeste</surname><given-names>DV</given-names></name>
<name><surname>Young</surname><given-names>R</given-names></name>
</person-group> (<year>1998</year>) <article-title>Assessment and treatment of bipolar disorder in the elderly</article-title>. <source>Drugs &amp; Aging</source> <volume>12</volume>: <fpage>205</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr46-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Efrati</surname><given-names>S</given-names></name>
<name><surname>Averbukh</surname><given-names>M</given-names></name>
<name><surname>Berman</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>N-Acetylcysteine ameliorates lithium-induced renal failure in rats</article-title>. <source>Nephrology Dialysis Transplantation</source> <volume>20</volume>: <fpage>65</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr47-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Even</surname><given-names>C</given-names></name>
<name><surname>Richard</surname><given-names>H</given-names></name>
<name><surname>Thuile</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Characteristics of voluntary participants versus nonparticipants in a psychoeducation program for euthymic patients with bipolar disorder</article-title>. <source>Journal of Nervous and Mental Disease</source> <volume>195</volume>: <fpage>262</fpage>–<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr48-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eyer</surname><given-names>F</given-names></name>
<name><surname>Pfab</surname><given-names>R</given-names></name>
<name><surname>Felgenhauer</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>26</volume>: <fpage>325</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr49-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fakhoury</surname><given-names>WK</given-names></name>
<name><surname>Wright</surname><given-names>D</given-names></name>
<name><surname>Wallace</surname><given-names>M</given-names></name>
</person-group> (<year>2001</year>) <article-title>Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline</article-title>. <source>International Clinical Psychopharmacology</source> <volume>16</volume>: <fpage>153</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr50-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferrie</surname><given-names>L</given-names></name>
<name><surname>Young</surname><given-names>AH</given-names></name>
<name><surname>McQuade</surname><given-names>R</given-names></name>
</person-group> (<year>2005</year>) <article-title>Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat</article-title>. <source>Journal of Psychopharmacology</source> <volume>19</volume>: <fpage>229</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr51-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferrie</surname><given-names>L</given-names></name>
<name><surname>Young</surname><given-names>AH</given-names></name>
<name><surname>McQuade</surname><given-names>R</given-names></name>
</person-group> (<year>2006</year>) <article-title>Effect of lithium and lithium withdrawal on potassium-evoked dopamine release and tyrosine hydroxylase expression in the rat</article-title>. <source>International Journal of Neuropsychopharmacology</source> <volume>9</volume>: <fpage>729</fpage>–<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr52-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finley</surname><given-names>PR</given-names></name>
<name><surname>O’Brien</surname><given-names>JG</given-names></name>
<name><surname>Coleman</surname><given-names>RW</given-names></name>
</person-group> (<year>1996</year>) <article-title>Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>16</volume>: <fpage>68</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr53-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finley</surname><given-names>PR</given-names></name>
<name><surname>Warner</surname><given-names>MD</given-names></name>
<name><surname>Peabody</surname><given-names>CA</given-names></name>
</person-group> (<year>1995</year>) <article-title>Clinical relevance of drug interactions with lithium</article-title>. <source>Clinical Pharmacokinetics</source> <volume>29</volume>: <fpage>172</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr54-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fliser</surname><given-names>D</given-names></name>
<name><surname>Franek</surname><given-names>E</given-names></name>
<name><surname>Joest</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Renal function in the elderly: impact of hypertension and cardiac function</article-title>. <source>Kidney International</source> <volume>51</volume>: <fpage>1196</fpage>–<lpage>1204</lpage>.</citation>
</ref>
<ref id="bibr55-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fountoulakis</surname><given-names>KN</given-names></name>
</person-group> (<year>2010</year>) <article-title>An update of evidence-based treatment of bipolar depression: where do we stand?</article-title> <source>Current Opinion in Psychiatry</source> <volume>23</volume>: <fpage>19</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr56-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fountoulakis</surname><given-names>KN</given-names></name>
<name><surname>Grunze</surname><given-names>H</given-names></name>
<name><surname>Panagiotidis</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2008a</year>) <article-title>Treatment of bipolar depression: an update</article-title>. <source>Journal of Affective Disorders</source> <volume>109</volume>: <fpage>21</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr57-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fountoulakis</surname><given-names>KN</given-names></name>
<name><surname>Vieta</surname><given-names>E</given-names></name>
<name><surname>Bouras</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2008b</year>) <article-title>A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic?</article-title> <source>International Journal of Neuropsychopharmacology</source> <volume>11</volume>: <fpage>269</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr58-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>MP</given-names></name>
<name><surname>Freeman</surname><given-names>SA</given-names></name>
</person-group> (<year>2006</year>) <article-title>Lithium: clinical considerations in internal medicine</article-title>. <source>American Journal of Medicine</source> <volume>119</volume>: <fpage>478</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr59-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frye</surname><given-names>MA</given-names></name>
<name><surname>Ketter</surname><given-names>TA</given-names></name>
<name><surname>Altshuler</surname><given-names>LL</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics</article-title>. <source>Journal of Affective Disorders</source> <volume>48</volume>: <fpage>91</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr60-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fyro</surname><given-names>B</given-names></name>
<name><surname>Pettersson</surname><given-names>U</given-names></name>
<name><surname>Sedvall</surname><given-names>G</given-names></name>
</person-group> (<year>1970</year>) <article-title>Serum lithium levels and side effects during administration of lithium carbonate and two slow release lithium preparations to human volunteers</article-title>. <source>Pharmacologia Clinica</source> <volume>2</volume>: <fpage>236</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr61-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gash</surname><given-names>AJ</given-names></name>
<name><surname>Chhabra</surname><given-names>S</given-names></name>
<name><surname>Eccleston</surname><given-names>D</given-names></name>
</person-group> (<year>1995</year>) <article-title>Lithium augmentation in a case of renal impairment: risk vs. benefit</article-title>. <source>Journal of Affective Disorders</source> <volume>34</volume>: <fpage>51</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr62-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geddes</surname><given-names>JR</given-names></name>
<name><surname>Burgess</surname><given-names>S</given-names></name>
<name><surname>Hawton</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials</article-title>. <source>The American Journal of Psychiatry</source> <volume>161</volume>: <fpage>217</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr63-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geddes</surname><given-names>JR</given-names></name>
<name><surname>Goodwin</surname><given-names>GM</given-names></name>
<name><surname>Rendell</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial</article-title>. <source>The Lancet</source> <volume>375</volume>: <fpage>385</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr64-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gershon</surname><given-names>S</given-names></name>
<name><surname>Chengappa</surname><given-names>KR</given-names></name>
<name><surname>Malhi</surname><given-names>GS</given-names></name>
</person-group> (<year>2009</year>) <article-title>Lithium specificity in bipolar illness: a classic agent for a classic disorder</article-title>. <source>Bipolar Disorders</source> <volume>11</volume>: <fpage>34</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr65-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gitlin</surname><given-names>M</given-names></name>
</person-group> (<year>1999</year>) <article-title>Lithium and the kidney – an updated review</article-title>. <source>Drug Safety</source> <volume>20</volume>: <fpage>231</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr66-0004867412437346">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>JF</given-names></name>
<name><surname>Berk</surname><given-names>M</given-names></name>
</person-group> (<year>2010</year>) <article-title>Rapid cycling bipolar disorder: phenomenology and treatment</article-title>. In: <person-group person-group-type="editor">
<name><surname>Yatham</surname><given-names>LN</given-names></name>
<name><surname>Maj</surname><given-names>M</given-names></name>
</person-group> (eds) <source>Bipolar Disorder</source>. <publisher-loc>Chichester</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>, pp.<fpage>333</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr67-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodwin</surname><given-names>FK</given-names></name>
<name><surname>Fireman</surname><given-names>B</given-names></name>
<name><surname>Simon</surname><given-names>GE</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Suicide risk in bipolar disorder during treatment with lithium and divalproex</article-title>. <source>The Journal of the American Medical Association</source> <volume>290</volume>: <fpage>1467</fpage>–<lpage>1473</lpage>.</citation>
</ref>
<ref id="bibr68-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodwin</surname><given-names>GM</given-names></name>
<name><surname>Malhi</surname><given-names>GS</given-names></name>
</person-group> (<year>2007</year>) <article-title>What is a mood stabilizer?</article-title> <source>Psychological Medicine</source> <volume>37</volume>: <fpage>609</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr69-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grandjean</surname><given-names>EM</given-names></name>
<name><surname>Aubry</surname><given-names>JM</given-names></name>
</person-group> (<year>2009a</year>) <article-title>Lithium: updated human knowledge using an evidence-based approach: Part II: clinical pharmacology and therapeutic monitoring</article-title>. <source>CNS Drugs</source> <volume>23</volume>: <fpage>331</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr70-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grandjean</surname><given-names>EM</given-names></name>
<name><surname>Aubry</surname><given-names>JM</given-names></name>
</person-group> (<year>2009b</year>) <article-title>Lithium: updated human knowledge using an evidence-based approach: Part III: clinical safety</article-title>. <source>CNS Drugs</source> <volume>23</volume>: <fpage>397</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr71-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grandjean</surname><given-names>EM</given-names></name>
<name><surname>Aubry</surname><given-names>JM</given-names></name>
</person-group> (<year>2009c</year>) <article-title>Lithium: updated human knowledge using an evidence-based approach: Part I: clinical efficacy in bipolar disorder</article-title>. <source>CNS Drugs</source> <volume>23</volume>: <fpage>225</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr72-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grunze</surname><given-names>H</given-names></name>
<name><surname>Vieta</surname><given-names>E</given-names></name>
<name><surname>Goodwin</surname><given-names>GM</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania</article-title>. <source>The World Journal of Biological Psychiatry</source> <volume>10</volume>: <fpage>85</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr73-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hallahan</surname><given-names>B</given-names></name>
<name><surname>Newell</surname><given-names>J</given-names></name>
<name><surname>Soares</surname><given-names>JC</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data</article-title>. <source>Biological Psychiatry</source> <volume>69</volume>: <fpage>326</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr74-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hokin</surname><given-names>LE</given-names></name>
<name><surname>Dixon</surname><given-names>JF</given-names></name>
<name><surname>Los</surname><given-names>GV</given-names></name>
</person-group> (<year>1996</year>) <article-title>A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the <italic>N</italic>-methyl <sc>d</sc>-aspartate receptor in monkey and mouse cerebral cortex slices</article-title>. <source>Advances in Enzyme Regulation</source> <volume>36</volume>: <fpage>229</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr75-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hopkins</surname><given-names>HS</given-names></name>
<name><surname>Gelenberg</surname><given-names>AJ</given-names></name>
</person-group> (<year>2000</year>) <article-title>Serum lithium levels and the outcome of maintenance therapy of bipolar disorder</article-title>. <source>Bipolar Disorders</source> <volume>2</volume>: <fpage>174</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr76-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>CH</given-names></name>
<name><surname>Liu</surname><given-names>PY</given-names></name>
<name><surname>Chen</surname><given-names>JH</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Electrocardiographic abnormalities as predictors for over-range lithium levels</article-title>. <source>Cardiology</source> <volume>103</volume>: <fpage>101</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr77-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hunter</surname><given-names>R</given-names></name>
</person-group> (<year>1988</year>) <article-title>Steady-state pharmacokinetics of lithium carbonate in healthy subjects</article-title>. <source>British Journal of Clinical Pharmacology</source> <volume>25</volume>: <fpage>375</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr78-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ikonomov</surname><given-names>OC</given-names></name>
<name><surname>Manji</surname><given-names>HK</given-names></name>
</person-group> (<year>1999</year>) <article-title>Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge</article-title>. <source>The American Journal of Psychiatry</source> <volume>156</volume>: <fpage>1506</fpage>–<lpage>1514</lpage>.</citation>
</ref>
<ref id="bibr79-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>HV</given-names></name>
<name><surname>Olafsson</surname><given-names>K</given-names></name>
<name><surname>Bille</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>Lithium every second day. A new treatment regimen?</article-title> <source>Lithium</source> <volume>1</volume>: <fpage>55</fpage>–<lpage>58</lpage> (<comment>Abstract only</comment>).</citation>
</ref>
<ref id="bibr80-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>GF</given-names></name>
<name><surname>Hunt</surname><given-names>GE</given-names></name>
</person-group> (<year>1984</year>) <article-title>Pharmacokinetics of lithium preparations in patients</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source> <volume>8</volume>: <fpage>63</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr81-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnston</surname><given-names>AM</given-names></name>
<name><surname>Eagles</surname><given-names>JM</given-names></name>
</person-group> (<year>1999</year>) <article-title>Lithium-associated clinical hypothyroidism. Prevalence and risk factors [see comment]</article-title>. <source>The British Journal of Psychiatry</source> <volume>175</volume>: <fpage>336</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr82-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karniol</surname><given-names>IG</given-names></name>
<name><surname>Dalton</surname><given-names>J</given-names></name>
<name><surname>Lader</surname><given-names>MH</given-names></name>
</person-group> (<year>1978</year>) <article-title>Acute and chronic effects of lithium chloride on physiological and psychological measures in normals</article-title>. <source>Psychopharmacology</source> <volume>57</volume>: <fpage>289</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr83-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>T</given-names></name>
<name><surname>Fujii</surname><given-names>K</given-names></name>
<name><surname>Shioiri</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>1996</year>) <article-title>Lithium side effects in relation to brain lithium concentration measured by lithium-7 magnetic resonance spectroscopy</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source> <volume>20</volume>: <fpage>87</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr84-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keck</surname><given-names>PE</given-names></name>
<name><surname>McElroy</surname><given-names>SL</given-names></name>
<name><surname>Keck</surname><given-names>PE</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Bipolar disorder, obesity, and pharmacotherapy-associated weight gain</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>64</volume>: <fpage>1426</fpage>–<lpage>1435</lpage>.</citation>
</ref>
<ref id="bibr85-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessing</surname><given-names>LV</given-names></name>
<name><surname>Forman</surname><given-names>JL</given-names></name>
<name><surname>Andersen</surname><given-names>PK</given-names></name>
</person-group> (<year>2010</year>) <article-title>Does lithium protect against dementia?</article-title> <source>Bipolar Disorders</source> <volume>12</volume>: <fpage>87</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr86-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessing</surname><given-names>LV</given-names></name>
<name><surname>Sondergard</surname><given-names>L</given-names></name>
<name><surname>Kvist</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study</article-title>. <source>Bipolar Disorders</source> <volume>9</volume>: <fpage>730</fpage>–<lpage>736</lpage>.</citation>
</ref>
<ref id="bibr87-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname><given-names>E</given-names></name>
<name><surname>Lavie</surname><given-names>P</given-names></name>
<name><surname>Meiraz</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Increased motor activity and recurrent manic episodes: predictors of rapid relapse in remitted bipolar disorder patients after lithium discontinuation</article-title>. <source>Biological Psychiatry</source> <volume>31</volume>: <fpage>279</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr88-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleindienst</surname><given-names>N</given-names></name>
<name><surname>Greil</surname><given-names>W</given-names></name>
</person-group> (<year>2004</year>) <article-title>Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder?</article-title> <source>Journal of Clinical Psychiatry</source> <volume>65</volume>: <fpage>966</fpage>–<lpage>974</lpage>.</citation>
</ref>
<ref id="bibr89-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleindienst</surname><given-names>N</given-names></name>
<name><surname>Severus</surname><given-names>WE</given-names></name>
<name><surname>Greil</surname><given-names>W</given-names></name>
</person-group> (<year>2007</year>) <article-title>Are serum lithium levels related to the polarity of recurrence in bipolar disorders? Evidence from a multi-center trial</article-title>. <source>International Clinical Psychopharmacology</source> <volume>22</volume>: <fpage>125</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr90-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleindienst</surname><given-names>N</given-names></name>
<name><surname>Severus</surname><given-names>WE</given-names></name>
<name><surname>Moller</surname><given-names>HJ</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Is polarity of recurrence related to serum lithium level in patients with bipolar disease?</article-title> <source>European Archives of Psychiatry and Clinical Neuroscience</source> <volume>255</volume>: <fpage>72</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr91-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kropf</surname><given-names>D</given-names></name>
<name><surname>Muller-Oerlinghausen</surname><given-names>B</given-names></name>
</person-group> (<year>1979</year>) <article-title>Changes in learning, memory, and mood during lithium treatment. Approach to a research strategy</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>59</volume>: <fpage>97</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr92-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kusalic</surname><given-names>M</given-names></name>
<name><surname>Engelsmann</surname><given-names>F</given-names></name>
</person-group> (<year>1999</year>) <article-title>Effect of lithium maintenance therapy on thyroid and parathyroid function</article-title>. <source>Journal of Psychiatry &amp; Neuroscience</source> <volume>24</volume>: <fpage>227</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr93-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazarus</surname><given-names>JH</given-names></name>
</person-group> (<year>1998</year>) <article-title>The effects of lithium therapy on thyroid and thyrotropin-releasing hormone</article-title>. <source>Thyroid</source> <volume>8</volume>: <fpage>909</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr94-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lenox</surname><given-names>RH</given-names></name>
<name><surname>McNamara</surname><given-names>RK</given-names></name>
<name><surname>Papke</surname><given-names>RL</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Neurobiology of lithium: an update</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>59</volume> <supplement>Suppl 6</supplement>: <fpage>37</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr95-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lepkifker</surname><given-names>E</given-names></name>
<name><surname>Iancu</surname><given-names>I</given-names></name>
<name><surname>Horesh</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Lithium therapy for unipolar and bipolar depression among the middle-aged and older adult patient subpopulation</article-title>. <source>Depression and Anxiety</source> <volume>24</volume>: <fpage>571</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr96-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindeman</surname><given-names>RD</given-names></name>
<name><surname>Tobin</surname><given-names>J</given-names></name>
<name><surname>Shock</surname><given-names>NW</given-names></name>
</person-group> (<year>1985</year>) <article-title>Longitudinal studies on the rate of decline in renal function with age</article-title>. <source>Journal of the American Geriatrics Society</source> <volume>33</volume>: <fpage>278</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr97-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Livingstone</surname><given-names>C</given-names></name>
<name><surname>Rampes</surname><given-names>H</given-names></name>
</person-group> (<year>2006</year>) <article-title>Lithium: a review of its metabolic adverse effects</article-title>. <source>Journal of Psychopharmacology</source> <volume>20</volume>: <fpage>347</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr98-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ljubicic</surname><given-names>D</given-names></name>
<name><surname>Letica-Crepulja</surname><given-names>M</given-names></name>
<name><surname>Vitezic</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Lithium treatments: single and multiple daily dosing</article-title>. <source>Canadian Journal of Psychiatry</source> <volume>53</volume>: <fpage>323</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr99-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Llewellyn</surname><given-names>A</given-names></name>
<name><surname>Stowe</surname><given-names>ZN</given-names></name>
<name><surname>Strader</surname><given-names>JR</given-names><suffix>Jr</suffix></name>
</person-group> (<year>1998</year>) <article-title>The use of lithium and management of women with bipolar disorder during pregnancy and lactation</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>59</volume> <supplement>Suppl 6</supplement>: <fpage>57</fpage>–<lpage>64</lpage>; <comment>discussion 65</comment>.</citation>
</ref>
<ref id="bibr100-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lombardi</surname><given-names>G</given-names></name>
<name><surname>Panza</surname><given-names>N</given-names></name>
<name><surname>Biondi</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Effects of lithium treatment on hypothalamic-pituitary-thyroid axis: a longitudinal study</article-title>. <source>Journal of Endocrinological Investigation</source> <volume>16</volume>: <fpage>259</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr101-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lydiard</surname><given-names>RB</given-names></name>
<name><surname>Gelenberg</surname><given-names>AJ</given-names></name>
</person-group> (<year>1982</year>) <article-title>Hazards and adverse effects of lithium</article-title>. <source>Annual Review of Medicine</source> <volume>33</volume>: <fpage>327</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr102-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Machado-Vieira</surname><given-names>R</given-names></name>
<name><surname>Manji</surname><given-names>HK</given-names></name>
<name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name>
</person-group> (<year>2009a</year>) <article-title>The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis</article-title>. <source>Bipolar Disorders</source> <volume>11</volume>: <fpage>92</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr103-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Machado-Vieira</surname><given-names>R</given-names></name>
<name><surname>Manji</surname><given-names>HK</given-names></name>
<name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name><etal/>
</person-group>. (<year>2009b</year>) <article-title>The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis</article-title>. <source>Bipolar Disorders</source> <volume>11</volume> <supplement>Suppl 2</supplement>: <fpage>92</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr104-0004867412437346">
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>McKnight</surname><given-names>RF</given-names></name>
<name><surname>Adida</surname><given-names>M</given-names></name>
<name><surname>Budge</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Lithium toxicity profile: a systematic review and meta-analysis</article-title>. <source>The Lancet</source> (<comment>in press</comment>).</citation>
</ref>
<ref id="bibr105-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mak</surname><given-names>TW</given-names></name>
<name><surname>Shek</surname><given-names>CC</given-names></name>
<name><surname>Chow</surname><given-names>CC</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source> <volume>83</volume>: <fpage>3857</fpage>–<lpage>3859</lpage>.</citation>
</ref>
<ref id="bibr106-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
</person-group> (<year>2010</year>) <article-title>The king is dead, long live the king! The restoration of BALANCE</article-title>. <source>Bipolar Disorders</source> <volume>12</volume>: <fpage>681</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr107-0004867412437346">
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Berk</surname><given-names>M</given-names></name>
</person-group> (<year>2012</year>) <article-title>Is the safety of lithium no longer in the balance?</article-title> <source>The Lancet</source> (<comment>in press</comment>).</citation>
</ref>
<ref id="bibr108-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Gershon</surname><given-names>S</given-names></name>
</person-group> (<year>2009</year>) <article-title>Ion men and their mettle</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>43</volume>: <fpage>1091</fpage>–<lpage>1095</lpage>.</citation>
</ref>
<ref id="bibr109-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Tanious</surname><given-names>M</given-names></name>
</person-group> (<year>2011</year>) <article-title>Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations</article-title>. <source>CNS Drugs</source> <volume>25</volume>: <fpage>289</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr110-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>D</given-names></name>
<name><surname>Berk</surname><given-names>M</given-names></name>
</person-group> (<year>2009a</year>) <article-title>Is lithium in a class of its own? A brief profile of its clinical use</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>43</volume>: <fpage>1093</fpage>–<lpage>1104</lpage>.</citation>
</ref>
<ref id="bibr111-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>DA</given-names></name>
<name><surname>Berk</surname><given-names>M</given-names></name>
</person-group> (<year>2009b</year>) <article-title>Medicating mood with maintenance in mind: bipolar depression pharmacotherapy</article-title>. <source>Bipolar Disorders</source> <volume>11</volume>: <fpage>55</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr112-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>D</given-names></name>
<name><surname>Cahill</surname><given-names>CM</given-names></name><etal/>
</person-group>. (<year>2009c</year>) <article-title>The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice</article-title>. <source>Drugs</source> <volume>69</volume>: <fpage>2063</fpage>–<lpage>2101</lpage>.</citation>
</ref>
<ref id="bibr113-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>DA</given-names></name>
<name><surname>Lampe</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>2009d</year>) <article-title>Clinical practice recommendations for bipolar disorder</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>119</volume>: <fpage>27</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr114-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>DA</given-names></name>
<name><surname>Porter</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2009e</year>) <article-title>Clinical practice recommendations for depression</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>119</volume>: <fpage>8</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr115-0004867412437346">
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Bargh</surname><given-names>D</given-names></name>
<name><surname>McIntyre</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>The clinical management of bipolar disorder complexity using a stratified model</article-title>. <source>Bipolar Disorders</source> (<comment>in press</comment>).</citation>
</ref>
<ref id="bibr116-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Chengappa</surname><given-names>KNR</given-names></name>
<name><surname>Gershon</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Hypomania: hype or mania?</article-title> <source>Bipolar Disorders</source> <volume>12</volume>: <fpage>758</fpage>–<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr117-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Chengappa</surname><given-names>KNR</given-names></name>
<name><surname>Gershon</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>Atypical mood stabilizers: a new role for neuroleptics?</article-title> <source>Bipolar Disorders</source> <volume>13</volume>: <fpage>583</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr118-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Mitchell</surname><given-names>PB</given-names></name>
<name><surname>Salim</surname><given-names>S</given-names></name>
</person-group> (<year>2003</year>) <article-title>Bipolar depression: management options</article-title>. <source>CNS Drugs</source> <volume>17</volume>: <fpage>9</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr119-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Tanious</surname><given-names>M</given-names></name>
<name><surname>Gershon</surname><given-names>S</given-names></name>
</person-group> (<year>2011b</year>) <article-title>The lithiumeter: a measured approach</article-title>. <source>Bipolar Disorders</source> <volume>13</volume>: <fpage>219</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr120-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mamiya</surname><given-names>K</given-names></name>
<name><surname>Sadanaga</surname><given-names>T</given-names></name>
<name><surname>Sekita</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Lithium concentration correlates with QTc in patients with psychosis</article-title>. <source>Journal of Electrocardiology</source> <volume>38</volume>: <fpage>148</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr121-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mander</surname><given-names>AJ</given-names></name>
<name><surname>Loudon</surname><given-names>JB</given-names></name>
</person-group> (<year>1988</year>) <article-title>Rapid recurrence of mania following abrupt discontinuation of lithium</article-title>. <source>The Lancet</source> <volume>332</volume>: <fpage>15</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr122-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manji</surname><given-names>HK</given-names></name>
<name><surname>Lenox</surname><given-names>RH</given-names></name>
</person-group> (<year>2000</year>) <article-title>Signaling: cellular insights into the pathophysiology of bipolar disorder</article-title>. <source>Biological Psychiatry</source> <volume>48</volume>: <fpage>518</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr123-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Markowitz</surname><given-names>GS</given-names></name>
<name><surname>Radhakrishnan</surname><given-names>JAI</given-names></name>
<name><surname>Kambham</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy</article-title>. <source>Journal of the American Society of Nephrology</source> <volume>11</volume>: <fpage>1439</fpage>–<lpage>1448</lpage>.</citation>
</ref>
<ref id="bibr124-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marmol</surname><given-names>F</given-names></name>
</person-group> (<year>2008</year>) <article-title>Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source> <volume>32</volume>: <fpage>1761</fpage>–<lpage>1771</lpage>.</citation>
</ref>
<ref id="bibr125-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mester</surname><given-names>R</given-names></name>
<name><surname>Toren</surname><given-names>P</given-names></name>
<name><surname>Mizrachi</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>Caffeine withdrawal increases lithium blood levels</article-title>. <source>Biological Psychiatry</source> <volume>37</volume>: <fpage>348</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr126-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morriss</surname><given-names>R</given-names></name>
<name><surname>Benjamin</surname><given-names>B</given-names></name>
<name><surname>Morriss</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Lithium and eGFR: a new routinely available tool for the prevention of chronic kidney disease</article-title>. <source>The British Journal of Psychiatry</source> <volume>193</volume>: <fpage>93</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr127-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller-Oerlinghausen</surname><given-names>B</given-names></name>
</person-group> (<year>2001</year>) <article-title>Arguments for the specificity of the antisuicidal effect of lithium</article-title>. <source>European Archives of Psychiatry and Clinical Neuroscience</source> <volume>251</volume>: <fpage>II/72</fpage>–<lpage>II/75</lpage>.</citation>
</ref>
<ref id="bibr128-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muzina</surname><given-names>DJ</given-names></name>
</person-group> (<year>2009</year>) <article-title>Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium</article-title>. <source>Bipolar Disorders</source> <volume>11</volume> <supplement>Suppl 2</supplement>: <fpage>84</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr129-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>F</given-names></name>
<name><surname>Oommen</surname><given-names>KM</given-names></name>
<name><surname>Wilting</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments</article-title>. <source>Bipolar Disorders</source> <volume>11</volume>: <fpage>559</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr130-0004867412437346">
<citation citation-type="book">
<collab>NICE</collab> (<year>2006</year>) <article-title>Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care: clinical guideline 38</article-title>. <publisher-loc>London</publisher-loc>: <publisher-name>National Institute for Health and Clincial Excellence</publisher-name>.</citation>
</ref>
<ref id="bibr131-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nivoli</surname><given-names>AMA</given-names></name>
<name><surname>Colom</surname><given-names>F</given-names></name>
<name><surname>Murru</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>New treatment guidelines for acute bipolar depression: a systematic review</article-title>. <source>Journal of Affective Disorders</source> <volume>129</volume>: <fpage>14</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr132-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nonaka</surname><given-names>S</given-names></name>
<name><surname>Hough</surname><given-names>CJ</given-names></name>
<name><surname>Chuang</surname><given-names>D-M</given-names></name>
</person-group> (<year>1998</year>) <article-title>Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting <italic>N</italic>-methyl-D-aspartate receptor-mediated calcium influx</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>95</volume>: <fpage>2642</fpage>–<lpage>2647</lpage>.</citation>
</ref>
<ref id="bibr133-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oakley</surname><given-names>PW</given-names></name>
<name><surname>Whyte</surname><given-names>IM</given-names></name>
<name><surname>Carter</surname><given-names>GL</given-names></name>
</person-group> (<year>2001</year>) <article-title>Lithium toxicity: an iatrogenic problem in susceptible individuals</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>35</volume>: <fpage>833</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr134-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>TW</given-names></name>
<name><surname>Klein</surname><given-names>PS</given-names></name>
</person-group> (<year>2009</year>) <article-title>Validating GSK3 as an in vivo target of lithium action</article-title>. <source>Biochemical Society Transactions</source> <volume>37</volume>: <fpage>1133</fpage>–<lpage>1138</lpage>.</citation>
</ref>
<ref id="bibr135-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okusa</surname><given-names>MD</given-names></name>
<name><surname>Crystal</surname><given-names>LJT</given-names></name>
</person-group> (<year>1994</year>) <article-title>Clinical manifestations and management of acute lithium intoxication</article-title>. <source>The American Journal of Medicine</source> <volume>97</volume>: <fpage>383</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr136-0004867412437346">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Pachoreck</surname><given-names>R</given-names></name>
</person-group> (<year>2001</year>) <article-title>Estimating creatinine clearance</article-title>. In: <person-group person-group-type="editor">
<name><surname>Murphy</surname><given-names>J</given-names></name>
</person-group> (ed) <source>Clinical Pharmacokinetics</source>. <edition>2nd edition.</edition> <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>American Society of Health System Pharmacists</publisher-name>, pp.<fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr137-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perlis</surname><given-names>R</given-names></name>
<name><surname>Sachs</surname><given-names>G</given-names></name>
<name><surname>Lafer</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data</article-title>. <source>The American Journal of Psychiatry</source> <volume>159</volume>: <fpage>1155</fpage>–<lpage>1159</lpage>.</citation>
</ref>
<ref id="bibr138-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perry</surname><given-names>PJ</given-names></name>
<name><surname>Dunner</surname><given-names>FJ</given-names></name>
<name><surname>Hahn</surname><given-names>RL</given-names></name><etal/>
</person-group>. (<year>1981</year>) <article-title>Lithium kinetics in single daily dosing</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>64</volume>: <fpage>281</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr139-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Phelan</surname><given-names>KM</given-names></name>
<name><surname>Mosholder</surname><given-names>AD</given-names></name>
<name><surname>Lu</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>64</volume>: <fpage>1328</fpage>–<lpage>1334</lpage>.</citation>
</ref>
<ref id="bibr140-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plenge</surname><given-names>P</given-names></name>
<name><surname>Amin</surname><given-names>M</given-names></name>
<name><surname>Agarwal</surname><given-names>AK</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Prophylactic efficacy of lithium administered every second day: a WHO multicentre study</article-title>. <source>Bipolar Disorders</source> <volume>1</volume>: <fpage>109</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr141-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plenge</surname><given-names>P</given-names></name>
<name><surname>Stensgaard</surname><given-names>A</given-names></name>
<name><surname>Jensen</surname><given-names>HV</given-names></name><etal/>
</person-group>. (<year>1994</year>) <article-title>24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy</article-title>. <source>Biological Psychiatry</source> <volume>36</volume>: <fpage>511</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr142-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Post</surname><given-names>RM</given-names></name>
<name><surname>Jimerson</surname><given-names>DC</given-names></name>
<name><surname>Bunney</surname><given-names>WE</given-names></name><etal/>
</person-group>. (<year>1980</year>) <article-title>Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide</article-title>. <source>Psychopharmacology</source> <volume>67</volume>: <fpage>297</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr143-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Post</surname><given-names>RM</given-names></name>
<name><surname>Speer</surname><given-names>AM</given-names></name>
<name><surname>Hough</surname><given-names>CJ</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Neurobiology of bipolar illness: implications for future study and therapeutics</article-title>. <source>Annals of Clinical Psychiatry</source> <volume>15</volume>: <fpage>85</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr144-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roose</surname><given-names>SP</given-names></name>
<name><surname>Nurnberger</surname><given-names>JI</given-names></name>
<name><surname>Dunner</surname><given-names>DL</given-names></name><etal/>
</person-group>. (<year>1979</year>) <article-title>Cardiac sinus node dysfunction during lithium treatment</article-title>. <source>The American Journal of Psychiatry</source> <volume>136</volume>: <fpage>804</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr145-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosa</surname><given-names>AR</given-names></name>
<name><surname>Marco</surname><given-names>M</given-names></name>
<name><surname>Fachel</surname><given-names>JM</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source> <volume>31</volume>: <fpage>217</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr146-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenqvist</surname><given-names>M</given-names></name>
<name><surname>Bergfeldt</surname><given-names>L</given-names></name>
<name><surname>Aili</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Sinus node dysfunction during long term lithium treatment</article-title>. <source>British Heart Journal</source> <volume>70</volume>: <fpage>371</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr147-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rybakowski</surname><given-names>JK</given-names></name>
<name><surname>Suwalska</surname><given-names>A</given-names></name>
</person-group> (<year>2010</year>) <article-title>Excellent lithium responders have normal cognitive functions and plasma BDNF levels</article-title>. <source>The International Journal of Neuropsychopharmacology</source> <volume>13</volume>: <fpage>617</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr148-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rybakowski</surname><given-names>JK</given-names></name>
<name><surname>Permoda-Osip</surname><given-names>A</given-names></name>
<name><surname>Borkowska</surname><given-names>A</given-names></name>
</person-group> (<year>2009</year>) <article-title>Response to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions</article-title>. <source>European Neuropsychopharmacology</source> <volume>19</volume>: <fpage>791</fpage>–<lpage>795</lpage>.</citation>
</ref>
<ref id="bibr149-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savitz</surname><given-names>J</given-names></name>
<name><surname>Drevets</surname><given-names>WC</given-names></name>
</person-group> (<year>2009</year>) <article-title>Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>33</volume>: <fpage>699</fpage>–<lpage>771</lpage>.</citation>
</ref>
<ref id="bibr150-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schou</surname><given-names>M</given-names></name>
<name><surname>Vestergaard</surname><given-names>P</given-names></name>
</person-group> (<year>1988</year>) <article-title>Prospective studies on a lithium cohort. 2. Renal function. Water and electrolyte metabolism</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>78</volume>: <fpage>427</fpage>–<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr151-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>J</given-names></name>
<name><surname>Pope</surname><given-names>M</given-names></name>
</person-group> (<year>2002</year>) <article-title>Nonadherence with mood stabilizers: prevalence and predictors</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>63</volume>: <fpage>384</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr152-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Segal</surname><given-names>J</given-names></name>
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Brook</surname><given-names>S</given-names></name>
</person-group> (<year>1998</year>) <article-title>Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial</article-title>. <source>Clinical Neuropharmacology</source> <volume>21</volume>: <fpage>176</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr153-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Severus</surname><given-names>WE</given-names></name>
<name><surname>Kleindienst</surname><given-names>N</given-names></name>
<name><surname>Evoniuk</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study</article-title>. <source>Journal of Affective Disorders</source> <volume>115</volume>: <fpage>466</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr154-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Severus</surname><given-names>WE</given-names></name>
<name><surname>Kleindienst</surname><given-names>N</given-names></name>
<name><surname>Seemuller</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>What is the optimal serum lithium level in the long-term treatment of bipolar disorder – a review?</article-title> <source>Bipolar Disorders</source> <volume>10</volume>: <fpage>231</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr155-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shafti</surname><given-names>SS</given-names></name>
</person-group> (<year>2010</year>) <article-title>Olanzapine vs. lithium in management of acute mania</article-title>. <source>Journal of Affective Disorders</source> <volume>122</volume>: <fpage>273</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr156-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shelley</surname><given-names>RK</given-names></name>
<name><surname>Silverstone</surname><given-names>T</given-names></name>
</person-group> (<year>1986</year>) <article-title>Single dose pharmacokinetics of 5 formulations of lithium: a controlled comparison in healthy subjects</article-title>. <source>International Clinical Psychopharmacology</source> <volume>1</volume>: <fpage>324</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr157-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shulman</surname><given-names>KI</given-names></name>
</person-group> (<year>2010</year>) <article-title>Lithium for older adults with bipolar disorder: should it still be considered a first-line agent?</article-title> <source>Drugs &amp; Aging</source> <volume>27</volume>: <fpage>607</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr158-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silverstone</surname><given-names>PH</given-names></name>
<name><surname>McGrath</surname><given-names>BM</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings</article-title>. <source>Bipolar Disorders</source> <volume>7</volume>: <fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr159-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silverstone</surname><given-names>T</given-names></name>
</person-group> (<year>2000</year>) <article-title>Is lithium still the maintenance treatment of choice for bipolar disorder?</article-title> <source>CNS Drugs</source> <volume>14</volume>: <fpage>81</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr160-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soares</surname><given-names>JC</given-names></name>
<name><surname>Boada</surname><given-names>F</given-names></name>
<name><surname>Spencer</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Brain lithium concentrations in bipolar disorder patients: preliminary (7) Li magnetic resonance studies at 3 T</article-title>. <source>Biological Psychiatry</source> <volume>49</volume>: <fpage>437</fpage>–<lpage>443</lpage>.</citation>
</ref>
<ref id="bibr161-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sproule</surname><given-names>BA</given-names></name>
<name><surname>Hardy</surname><given-names>BG</given-names></name>
<name><surname>Shulman</surname><given-names>KI</given-names></name>
</person-group> (<year>2000</year>) <article-title>Differential pharmacokinetics of lithium in elderly patients</article-title>. <source>Drugs &amp; Aging</source> <volume>16</volume>: <fpage>165</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr162-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Squire</surname><given-names>LR</given-names></name>
<name><surname>Judd</surname><given-names>LL</given-names></name>
<name><surname>Janowsky</surname><given-names>DS</given-names></name><etal/>
</person-group>. (<year>1980</year>) <article-title>Effects of lithium carbonate on memory and other cognitive functions</article-title>. <source>The American Journal of Psychiatry</source> <volume>137</volume>: <fpage>1042</fpage>–<lpage>1046</lpage>.</citation>
</ref>
<ref id="bibr163-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steckler</surname><given-names>TL</given-names></name>
</person-group> (<year>1994</year>) <article-title>Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience in a psychiatric hospital</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>14</volume>: <fpage>336</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr164-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suppes</surname><given-names>T</given-names></name>
<name><surname>Marangell</surname><given-names>LB</given-names></name>
<name><surname>Bernstein</surname><given-names>IH</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression</article-title>. <source>Journal of Affective Disorders</source> <volume>111</volume>: <fpage>334</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr165-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tajes</surname><given-names>M</given-names></name>
<name><surname>Yeste-Velasco</surname><given-names>M</given-names></name>
<name><surname>Zhu</surname><given-names>X</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Activation of Akt by lithium: pro-survival pathways in aging</article-title>. <source>Mechanisms of Ageing and Development</source> <volume>130</volume>: <fpage>253</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr166-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomsen</surname><given-names>K</given-names></name>
<name><surname>Leyssac</surname><given-names>PP</given-names></name>
</person-group> (<year>1986</year>) <article-title>Acute effects of various diuretics on lithium clearance. Studies in rats on medium and low sodium diet</article-title>. <source>Renal Physiology</source> <volume>9</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr167-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timmer</surname><given-names>RT</given-names></name>
<name><surname>Sands</surname><given-names>JM</given-names></name>
</person-group> (<year>1999</year>) <article-title>Lithium intoxication</article-title>. <source>Journal of the American Society of Nephrology</source> <volume>10</volume>: <fpage>666</fpage>–<lpage>674</lpage>.</citation>
</ref>
<ref id="bibr168-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tohen</surname><given-names>M</given-names></name>
<name><surname>Chengappa</surname><given-names>KN</given-names></name>
<name><surname>Suppes</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy</article-title>. <source>Archives of General Psychiatry</source> <volume>59</volume>: <fpage>62</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr169-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Erp</surname><given-names>TGM</given-names></name>
<name><surname>Thompson</surname><given-names>PM</given-names></name>
<name><surname>Kieseppä</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins</article-title>. <source>Human Brain Mapping</source> Epub ahead of print <day>31</day> <month>March</month> <year>2011</year>. DOI: 10.1002/hbm.21239<pub-id pub-id-type="doi">10.1002/hbm.21239</pub-id>.</citation>
</ref>
<ref id="bibr170-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Lieshout</surname><given-names>RJ</given-names></name>
<name><surname>MacQueen</surname><given-names>GM</given-names></name>
</person-group> (<year>2010</year>) <article-title>Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review</article-title>. <source>The British Journal of Psychiatry</source> <volume>196</volume>: <fpage>266</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr171-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vestergaard</surname><given-names>P</given-names></name>
<name><surname>Poulstrup</surname><given-names>I</given-names></name>
<name><surname>Schou</surname><given-names>M</given-names></name>
</person-group> (<year>1988</year>) <article-title>Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>78</volume>: <fpage>434</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr172-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieta</surname><given-names>E</given-names></name>
<name><surname>Locklear</surname><given-names>J</given-names></name>
<name><surname>Gunther</surname><given-names>O</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Treatment options for bipolar depression: a systematic review of randomized, controlled trials</article-title>. <source>Journal of Clinical Pyschopharmacology</source> <volume>30</volume>: <fpage>579</fpage>–<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr173-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viguera</surname><given-names>AC</given-names></name>
<name><surname>Cohen</surname><given-names>LS</given-names></name>
</person-group> (<year>1998</year>) <article-title>The course and management of bipolar disorder during pregnancy</article-title>. <source>Psychopharmacology Bulletin</source> <volume>34</volume>: <fpage>339</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr174-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viguera</surname><given-names>AC</given-names></name>
<name><surname>Newport</surname><given-names>DJ</given-names></name>
<name><surname>Ritchie</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Lithium in breast milk and nursing infants: clinical implications</article-title>. <source>The American Journal of Psychiatry</source> <volume>164</volume>: <fpage>342</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr175-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vincent</surname><given-names>A</given-names></name>
<name><surname>Baruch</surname><given-names>P</given-names></name>
<name><surname>Vincent</surname><given-names>P</given-names></name>
</person-group> (<year>1993</year>) <article-title>Early onset of lithium-associated hypothyroidism</article-title>. <source>Journal of Psychiatry &amp; Neuroscience</source> <volume>18</volume>: <fpage>74</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr176-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Widerlov</surname><given-names>E</given-names></name>
</person-group> (<year>1976</year>) <article-title>A comparative double-blind study of the side effects of Litarex and Lithionit Durettes</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>54</volume>: <fpage>294</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr177-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wijeratne</surname><given-names>C</given-names></name>
<name><surname>Draper</surname><given-names>B</given-names></name>
</person-group> (<year>2011</year>) <article-title>A reformulation of current recommendations for target serum lithium concentration according to clinical indication, age and physical comorbidity</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>45</volume>: <fpage>1026</fpage>–<lpage>1032</lpage>.</citation>
</ref>
<ref id="bibr178-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilkinson</surname><given-names>D</given-names></name>
<name><surname>Holmes</surname><given-names>C</given-names></name>
<name><surname>Woolford</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Prophylactic therapy with lithium in elderly patients with unipolar major depression [see comment]</article-title>. <source>International Journal of Geriatric Psychiatry</source> <volume>17</volume>: <fpage>619</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr179-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilting</surname><given-names>I</given-names></name>
<name><surname>de Vries</surname><given-names>F</given-names></name>
<name><surname>Thio</surname><given-names>BM</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Lithium use and the risk of fractures</article-title>. <source>Bone</source> <volume>40</volume>: <fpage>1252</fpage>–<lpage>1258</lpage>.</citation>
</ref>
<ref id="bibr180-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingo</surname><given-names>AP</given-names></name>
<name><surname>Wingo</surname><given-names>TS</given-names></name>
<name><surname>Harvey</surname><given-names>PD</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Effects of lithium on cognitive performance: a meta-analysis</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>70</volume>: <fpage>1588</fpage>–<lpage>1597</lpage>.</citation>
</ref>
<ref id="bibr181-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yatham</surname><given-names>LN</given-names></name>
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>O’Donovan</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies</article-title>. <source>Bipolar Disorders</source> <volume>7</volume>: <fpage>5</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr182-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yatham</surname><given-names>LN</given-names></name>
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>O’Donovan</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007</article-title>. <source>Bipolar Disorders</source> <volume>8</volume>: <fpage>721</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr183-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yatham</surname><given-names>LN</given-names></name>
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Schaffer</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009</article-title>. <source>Bipolar Disorders</source> <volume>11</volume>: <fpage>225</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr184-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildiz</surname><given-names>A</given-names></name>
<name><surname>Vieta</surname><given-names>E</given-names></name>
<name><surname>Leucht</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials</article-title>. <source>Neuropsychopharmacology</source> <volume>36</volume>: <fpage>375</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr185-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>K</given-names></name>
<name><surname>Smith</surname><given-names>B</given-names></name>
<name><surname>Kumar</surname><given-names>R</given-names></name>
</person-group> (<year>1999</year>) <article-title>Psychotropic drugs in mothers’ milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding</article-title>. <source>Journal of Psychopharmacology</source> <volume>13</volume>: <fpage>64</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr186-0004867412437346">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>AH</given-names></name>
<name><surname>Hammond</surname><given-names>JM</given-names></name>
</person-group> (<year>2007</year>) <article-title>Lithium in mood disorders: increasing evidence base, declining use?</article-title> <source>The British Journal of Psychiatry</source> <volume>191</volume>: <fpage>474</fpage>–<lpage>476</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>